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A BSTR A C T

Drug delivery refers to approaches, formulations, technologies, and systems for
transporting a drug in the body. The purpose is to enhance the drug efficacy and to reduce
side reactions, which can significantly improve treatment outcomes. Halloysite is a
naturally occurred alumino-silicate clay with a tubular structure. It is a biocompatible
material with a big surface area which can be used for attachm ent o f targeted molecules.
Besides, loaded m olecules can present a sustained release manner in solution. These
properties make halloysite nanotubes (HNTs) a good option for drug delivery.
In this study, a drug delivery system was built based on halloysite via three
different fabrication methods: physical adsorption, vacuum loading and layer-by-layer
coating. M ethotrexate was used as the model drug. Factors that may affect performance
in both drug loading and release were tested. Results showed that methotrexate could be
incorporated within the HNTs system and released in a sustained manner. Layer-by-layer
coating showed a better potential than the other two m ethods in both MTX loading and
release. Besides, lower pH could greatly improve MTX loading and release while the
increased num ber o f polyelectrolytes bilayers had a limited impact.
Osteosarcom a is the most com mon primary bone malignancy in children and
adolescents. Postoperative recurrence and metastasis has become one o f the leading
causes for patient death after surgical remove o f the tum or mass. A strategy could be a
sustained release o f chem otherapeutics directly at the primary tum or sites where

recurrence would mostly occur. Then, this HNTs based system was tested with
osteosarcom a cells in vitro to show the potential o f delivering chem otherapeutics in the
treatm ent o f osteosarcom a. M ethotrexate was incorporated within HNTs with a layer-bylayer coating technique, and drug coated HNTs were filled into nylon - 6 which is a
common material for surgical sutures in industry. Results showed that (1) methotrexate
could be released in a sustained manner; ( 2 ) cytotoxicity test confirm ed the
biocom patibility o f HNTs and m ethotrexate coated HNTs; (3) proliferation test
confirm ed the growth inhibition o f released m ethotrexate on osteosarcom a cells; and (4)
nylon - 6 could prolong the sustained release o f m ethotrexate from polyelectrolytes coated
HNTs.
A nother application com es from the prevention o f surgical site infection. It is a
com mon com plication in surgery, which may prolong hospital stay, increase mortality
rate, and cause additional financial burden for patients. By directly releasing antibiotics at
the surgical site, it is supposed to enhance the drug efficacy and improve the treatment
outcome. Therefore, the same HNTs based system was tested with E. coli in vitro to show
the potential o f delivering antibiotics to enhance the prevention o f surgical site infection.
Nitrofurantoin was incorporated within HNTs using the layer-by-layer coating technique,
and the drug coated HNTs were filled into nylon - 6 again. Results showed that (1)
nitrofurantoin could be incorporated with this HNTs based drug delivery system, and
released in a sustained manner; (2 ) nylon - 6 could prolong the sustained release o f
nitrofurantoin from polyelectrolytes coated HNTs; and (3) released nitrofurantoin could
severely inhibit E. coli growth.

Therefore, a tunable drug delivery system based on HNTs was developed, and a
great potential o f medical application in drug delivery was shown.
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C H A PTER 1
IN TR O D U C TIO N

1.1

Objective

This dissertation introduces a newly formed drug delivery system based on
halloysite nanotubes (HNTs). By applying several fabrication methods, biologically
functional molecules (such as DNA, RNA, proteins, and drugs) could be loaded within
this nano-vehicle, and released in a sustained/controlled manner at the sites o f action.
Subsequently, these released m olecules could act on the surrounding tissues or cells. In
this way, biom olecules can be directly delivered to their action sites, which would
increase their efficacy and safety, and avoid potential side reactions as well.

1.2
1.2.1

Background

Nanotechnology
In the 21st Century, nanotechnology has becom e one o f the leading elements

advancing technology, and nanotech-based products have impacted almost everything we
touch in life, such as medicines, chemicals, biologies, and pharm aceuticals [1]. In
particular, the breakthroughs o f nano-engineering made in the field o f drug delivery and
formulation developm ent have contributed significantly to the growth o f
nanopharm aceuticals [2]. Because o f the inherent potential o f nanopharmaceutical
products to overcom e solubility and stability issues, localized drug delivery, enhanced

2

drug efficacy, the need to avoid unwanted side reactions, and assistance in diagnosis via
in vivo imaging, increased research efforts have been focused on the specific fields o f
drug delivery and formulation.
1.2.2

Drug Delivery
During the past few years, an increased number o f researchers have realized the

importance o f effective drug delivery, which is a fundamental part o f drug development.
Many drug delivery system s have been developed and have entered the market, such as
liposom es and nanoparticles. Theoretically speaking, an ideal drug delivery system
should improve the stability, absorption, and therapeutic concentration o f the drug within
the target environm ent, as well as the long-term release o f the drug at the target site.
Additionally, it should help reduce the frequency o f drug adm inistration and improve
patient com fort [ 1 ].
1.2.3

M arket Need
In the pharmaceutical industry, the field o f drug delivery offers a new direction

for expanding drug markets, because newly developed nanotechnology could assist in
making current drugs more efficacious and improve their competition against other
counterparts. In 2012, it was estim ated that about 13% o f the global pharmaceutical
market was related to the sale o f products based on a drug delivery system [3],

1.3

Specific Aims

In this dissertation, a halloysite-based drug delivery system was developed with
different fabrication methods. Factors that could affect the loading and releasing process
were tested to obtain more control over the newly formed nano-vehicle. Three fabrication
methods were com pared in the perform ance o f both loading and release results. The best
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method was used in subsequent experiments. Two individual in vitro tests were used to
verify the potential o f using an HNT based system for drug delivery. M ethotrexate
(M TX) and nitrofurantoin (NFT) were used as model drugs, and osteosarcom a cells and
Escherichia coli (E. coli) were used for tested targets to individually show the feasibility
in the treatm ent o f osteosarcom a and surgical site infection.

1.4
1.4.1

Projects and Hypotheses

Project 1
Three fabrication methods were used to dope m ethotrexate with HNTs. By

com paring the loading and release results, we may be able to identify the impact o f
loading and release processes, such as the pH, temperature, concentration, spatial
structure, polyelectrolytes, etc. In this way, inform ation on the loading and release
processes with the HNTs based drug delivery system may be used to improve the
delivery system.
1.4.2

Project 2
In the first in vitro test, osteosarcom a cells were used as the disease model,

because metastasis and recurrence are still the most com mon causes leading to patient
death after surgical remove o f the prim ary tum or mass. MTX

isa com monly used drug in

the treatment o f osteosarcom a and was used as the model drug for delivery. MTX was
supposed to be loaded within the HNTs based drug delivery system, and could be
released subsequently in a sustained manner. Besides, released MTX could keep its
biological function intact during the whole process, and act on the osteosarcom a cells. In
this way, the HNTs based drug delivery system showed a potential to deliver
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chem otherapeutics to target sites o f the tum or to prevent postoperative metastasis and/or
recurrence.
1.4.3

Project 3
In the second in vitro test, surgical site infection was the targeted disease model,

as it is a common com plication in surgery. It causes unnecessary direct health problem s
and indirect social cost to patients, and increases the financial burden on society.
Nitrofurantoin was selected as the model drug, and E. coli was used as the target
pathogen. NFT was supposed to be loaded within the HNTs based drug delivery system,
and could be released in a sustained m anner in bacterial broth with its biological function
intact. Then, it could subsequently act on the bacteria and inhibit its growth. The same
result should be achieved when NFT coated HNTs were filled within nylon - 6 which is a
routine material for sutures. In this way, antibiotics could be delivered to the surgical site
and be released locally to prevent the potential infection.

1.5

Exclusions

In this dissertation, all o f the work was focused on passive drug delivery. Active
drug delivery is more com plicated and would become the next step if results from
preliminary experiment are satisfied.

1.6

Outline o f Dissertation

Chapter 1 introduces the objective and general background for this dissertation. It
also describes the specific projects and associated hypotheses which will be discussed in
subsequent chapters, and presents the organization o f this dissertation.
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Chapter 2 gives a brief literature review concerning the main concepts and
technologies related to this dissertation: nanotechnology, drug delivery, halloysite
nanotubes, layer-by-layer technique, osteosarcoma, and surgical site infection.
Chapter 3 describes the methods and instruments used in the experiment.
Chapter 4 introduces current fabrication methods which can be applied to prepare
the HNTs based drug delivery system. By com paring the loading and release results,
factors which may affect the loading and release process were discussed, such as pH,
concentration, spatial structure, and polyelectrolytes. Besides, advantages and limitations
were compared among the studied fabrication methods, and the appropriate method could
be selected for subsequent projects.
Chapter 5 presents the application o f using HNTs based drug delivery system to
deliver MTX to osteosarcom a cells in vitro showing its potential in the treatment o f
postoperative recurrence.
Chapter
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describes the application o f using HNTs based drug delivery system to

deliver NFT to E. coli in vitro showing its potential to prevent postoperative surgical site
infection.
Chapter 7 concludes the results o f the dissertation, and recom mends direction for
future study.

CH A PTER 2
LIT ERATU RE REVIEW

2.1
2.1.1

Nanom edicine

Nanotechnology and M edicine
The em erging trends and development o f nanotechnology have been attracting

more and more attention, especially in medical fields. A specific term called
nanomedicine is used to describe the application o f nanotechnology in medicine. There
have been many promising applications o f nanomedicine including, but not limited to,
drug delivery, in vitro diagnosis, in vivo imaging, therapy techniques, biomaterials, and
tissue engineering, which are summarized in Table 2-1 [4], Some o f them have been
realized and their products have entered the marketplace, while others are still under
active research. Experts estimated that the global market o f nanotechnology-based
products in medical fields would grow to $ 70-160 billion by 2015 [5-6],

Table 2-1: Nanoscale application in medicine [4].
Subm edical

Application

Field
Nanotechnology based drug delivery systems can (1) enhance
the therapeutic efficacy and minimize adversities associated
Drug Delivery

with available drugs; (2) enable new classes o f therapeutics;
and (3) encourage the re-investigation o f pharmaceutically
suboptimal but biologically active new m olecular entities that
were previously considered undeveloped.
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Nanoscale sensors (e.g., nanowires, nanotubes, nanoparticles,
cantilevers, and m icro/nanoarrays) can enable fast and high
In Vitro

throughput detection o f disease biom arkers with higher

Diagnostics

sensitivity and lower sample consumption. Nanotechnology
also offers hope for the early detection o f viruses, bacteria, and
circulating tum or cells, as well as for single cell analysis.
Targeted im aging nanoprobes (e.g., magnetic nanoparticles,
quantum dots, and carbon nanotubes) could provide a faster,
less invasive, and more accurate way to diagnose diseases
(e.g., cancer) at their earliest stages and m onitor disease

In Vivo

progression. Some other possible opportunities include
reporting in vivo efficacy o f therapeutics and tracking

Imaging

nanocarrier biodistribution in the body. In addition, imaging
nanoprobes could help surgeons to locate tum ors and their
margins, identify important adjacent structures, and map
sentinel lymph nodes.
Certain nanom aterials have unique therapeutic properties that
differ from conventional drugs, and can, therefore, be directly
Therapy

used to treat diseases. For example, hafnium oxide- and gold-

Techniques

based nanoparticles can greatly enhance X-ray therapy; gold
nanoshells/nanorods carbon nanotubes, magnetic nanoparticles
can induce hypotherm ia to kill cancer cells; and
nanocrystalline silver is being used as an antimicrobial agent.
Biocompatible nanom aterials that have optimal mechanical
properties can be used as medical implants, such as dental

Biomaterials

restoratives and bone substitutes (also categorized as hardtissue engineering.). Nanocoatings or nanostructured surfaces
can also improve the biocompatibility and adhesion o f
biomaterials.
Nanotechnology can enable the design and fabrication o f

Tissue

biocompatible scaffolds at the nanoscale and control the

Engineering

spatiotemporal release o f biological factors, resembling native
extracellular matrix, to direct cell behaviors, and eventually
lead to the creation o f implantable tissues.

2.1.2

N anotechnology and Drug Development
Drug discovery and developm ent is one o f the many fields in medicine that

benefit from nanotechnology. In the pharmaceutical industry, an ideal candidate o f new
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molecular entity (NM E) for potential drug developm ent should dem onstrate potent
biological activity, appropriate w ater solubility, and enough circulating half-life.
Actually, some NM Es have adequate bioactivity but show poor w ater solubility or short
half-life period in circulation, while others have good solubility and half-life period but
weak biological function. In either case, there is always a degree o f com prom ise, and the
drug developm ental potential is less ideal than expected. Fortunately, breakthroughs in
nanotechnology make it possible to address some o f these shortcom ings associated with
potential NM Es. For exam ple, nanotechnology can significantly im prove the
pharmacological properties (like w ater solubility and circulating half-life in blood) o f
such NM Es, leading to the discovery o f optimally safe and effective drug candidates [4].
In this way, nanotechnology could revolutionize the rules and possibilities o f developing
new drugs. In fact, many current nanotechnology-based therapeutic products have been
validated through the im provem ent o f previously approved drugs, and some novel classes
o f nano-therapeutics are now underway [7-9].

2.2
2.2.1

Drug Delivery

N anom aterials for Drug Delivery
N owadays, m ore and more papers are published every day about drug delivery

based on nanom aterials that show an increasing attention to the research o f
nanom aterials. Obviously, nanom aterials offer many advantages (Table 2-2) as drug
delivery vehicles. Drug particles are expected to go through a long route inside the
human body to reach scheduled sites and act on targeted tissues and cells. However, there
are some physiological hindrances that may greatly decrease the drug efficacy and create
the need for using nanom aterials to assist in the delivery o f scheduled drugs. Therefore,
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first, nanoparticles must have suitable dim ensions that allow them to smoothly pass tiny
capillaries with 5-6 microns in diameter. A range o f 10-100 nm is required for particles to
proceed through systemic circulation [5]. Then access to various sites inside the body is
available. Secondly, nanoparticles are more easily consumed by cells via internalization
than larger micromolecules, which can help increase drug efficacy. The integrated drug
could be released from the nanoparticles and act more efficiently inside the cytoplasm.
Thirdly, nanoparticles have the potential to be used for targeted drug delivery at the
specific disease area, improving drug efficiency. Fourthly, the controlled release o f drugs
from nanoparticles can help lessen undesired side reactions. Therefore, nanom aterials
hold great potential for the im provement o f the overall therapeutic index, offering another
option for drug delivery.

Table 2-2: Advantages o f nanom aterials in drug delivery.
Advantages
(1)

Ability to pass through narrow capillaries and accessibility o f remote
areas

(2)

Easily consumed

(3)

Delivery at specific diseased area via active or passive targeting

(4)

Controlled release

In fact, there has been a long history o f applying nanotechnology in drug delivery.
Since liposomes were first introduced as carriers for drugs and proteins in 1960 [6],
nanotechnology has entered the field o f nanom edicine, and there have been many
nanotech-based products approved by the FDA or still in clinical trials (Figure 2-1) [7-9].
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Liposome and
drug delivery
in1960s

First liposomebased siRNA
delivery in 2001

First targeted
liposome in 1980

First targeted
deliveiy of siRNA
entered clinical
trials in 2008
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First controlled
release polymer
system for
macromolecules
in 1976

First polymerdrug conjugate
approved by
FDA in 1990

First clinical study of
a targeted polvmerdrug conjugate 2002

Dendrimersome
first described
2010

Figure 2-1: Timeline o f nanotechnology-based drug delivery systems. Here, we
highlight some delivery systems that serve as important milestones throughout the
history o f drug delivery. Adapted from “Nanotechnology in Drug Delivery and Tissue
Engineering: From Discovery to A pplications” by Jinjun Shi, et al, 2010, Nano Letters,
10(9), p. 3223-3230.

The main purposes o f using nanotechnology in drug delivery applications are (1)
to improve the delivery o f water insoluble drugs [7]; (2) to deliver large m acromolecule
drugs into intracellular sites o f action; (3) to co-deliver two or more drugs or therapeutic
agents for com bination treatment; (4) to transport drugs across tight epithelial and
endothelial barriers [8]; (5) targeted delivery o f drugs in a cell- or tissue-specific manner;
(6) real-time read on the in vivo efficacy o f a therapeutic agent, and (7) visualization o f
sites o f drug delivery by combining therapeutic agents with imaging probes [9],
2.2.2

Classification o f Drug Delivery
According to the mechanism o f how the drugs are delivered to action sites, drug

delivery can be classified as two types: passive and active delivery (Table 2-3).

Table 2-3: Drug delivery: passive targeting versus active targeting [10].
Passive Targeting

(1)

Active Targeting

Utilizes special deviated

Depends on targeting ligands and

conditions prevailing in the

corresponding biom arkers that are

diseased area

overexpressed in diseased cells or
tissues

(2)

Less selective

Highly selective

(3)

Restricted in use

Very versatile

(4)

More likely to produce side

Less likely to induce side effects

effects
Passive delivery facilitates the deposition o f nanoparticles incorporated with
drugs in their action sites by taking advantage o f certain biophysical properties. The most
com mon exam ples are direct drug injection and catheterization. Spontaneous drug
accumulation in a diseased area with leaky vasculature is another form o f passive
delivery. This approach is based on the preparation o f a drug carrier com plex that can
avoid removal through the body mechanisms (like metabolism, excretion, opsonisation,
and phagocytosis) and stay in the blood circulation allowing its transm ission to targeted
disease areas. An important application o f this mechanism is the delivery o f
chem otherapeutics in the treatment o f cancer, where a special phenom enon called
enhanced permeability and retention (EPR) could be well utilized. In oncology, there are
some unique structural features shared by many solid tumors, including hypervasculature,
defective vascular architecture, and impaired lymphatic drainage leading to the wellcharacterized EPR effect [10]. These distinctive characteristics are inherent to the tum or
milieu, but are not normally present in healthy tissues [11]. Besides, properties o f the
nanoparticles which include m olecular size, shape, and surface charge could also affect
the delivery. [11]. For exam ple, previous studies have confirmed that macromolecules
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with a molecular weight higher than the renal threshold (40 kDa) tend to accumulate
preferentially in neoplastic tissues upon intravenous adm inistration [17-18]. The normal
vasculature endowed with tight junctions is impermeable to molecules sized over 2-4 nm,
and can keep the nanoparticles within the circulation; however, the leaky vasculature o f
neoplastic tissue allows m acromolecules with a diameter under 600 nm to extravasate
into the neoplastic tissues [12]. Additionally, most tumors only have a poorly-developed
lymphatic system, which would help these extravasated nanoparticles stagnate within the
neoplastic tissue [20-21], Another exam ple com es from the surface property.
Nanoparticles coated with polyethylene glycol (PEG) and sized between 200 nm and 500
nm could slip through a barrier o f human mucus lining organs such as lungs,
gastrointestinal tract, and cervicovaginal tract [5]. In this way, it is possible to deliver
chem otherapeutics to tumors within the aforem entioned organs.
Different from the passive approach, active delivery uses targeting ligands that
can interact with some degree o f exclusivity with specific biomarkers overexpressed on
targeted cells or tissues. These com mon ligands include sugars, folic acid, peptides, and
explicitly engineered antibodies [5], They are connected with the drug loaded
nanoparticles and direct them to targets in the body such as receptors, lipids, antigens,
and proteins. For example, in M iao’s study [13], functionalizing hydroxypropyl-bcyclodextrin copolym er nanoparticles were developed for targeting delivery o f paclitaxel
to integrin d y ^-rich tum or cells. In another study, Tomoki Sugiyama et al [14] used
VEGFR (vascular endothelial growth factor receptor)-1-targeted peptide APRPG and
integrin a v[T-targeted peptide GRGDS to decorate liposomes synergistically and tested
them on proliferative HUVECs (human umbilical vein endothelial cells). Results showed
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that these dual-targeting liposom es could highly accumulate in tum or tissues o f tumorbearing mice, and intratumoral distribution study indicated that they could also localize
on angiogenic vessels as well as distribute around these vessels. Although more
com plicated than the passive approach, active delivery offers the widest opportunities and
alternatives.
2.2.3

Current Status and Challenges
Ideally, a drug administered should reach the diseased site in the human body

without affecting the healthy tissues and organs en route. After reaching the target, it can
release the ingredients at the scheduled time in the appropriate dosage to heal. Further,
after the diseased part is cured, the remnant drug could be expelled from the body to
avoid any side effects. Especially in the treatment o f cancer, drugs with high efficacy and
little side effect are always the first-line option. Additional delivery vehicles are
developed to help achieve that ideal goal. For example, some common nanosystems
include liposom es [24-26], polymeric micelles [27-30], polym er-drug conjugates [ 15],
and dendrim ers [16]. There are also some new er types developed or still under research,
which include nanocages, nanogels, nanofibers, nanoshells, nanorods, and nanocontainers
[5],
However, there is still a long way to go from the current nanoproducts to the
ideally expected one. The translation o f active delivery from laboratory to clinical
application is not as smooth as people expect. One possible reason is the com plicated
m anufacturing process, which includes biomaterial assembly, ligand coupling/insertion,
and purification [4]. Another one is targeting ligands. Besides, there are some other
considerable variables, such as ligand biocompatibility, cell specificity, binding affinity,
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mass production, purity, ligand surface density and arrangem ent, spacer type and length
dividing ligand m olecules and nanoparticles [33-34], In fact, o f the current
nanotechnology-based drug delivery system s that are in the market or still under clinical
trials, the majority are passive delivery. Obviously, compared to the active approach, it is
relatively simple and the requirement is not that harsh. The drug loaded nanosvstems
would accum ulate at the diseased area by utilizing unique characteristics inherent to the
disease. Therefore, a thorough understanding o f biological features is necessary for
designing and preparing drug loaded nanosystem s.
In this dissertation, an HNT based drug delivery nanosystem was built using the
passive approach. The specific expected result o f using this tool was based on some
characteristics o f biological environm ent inherent to the disease. In other words, the
biological characteristics o f the diseased area were utilized to enhance the efficacy as
well as to reduce side effects o f the scheduled drugs, leading to im provem ent o f the
overall therapeutic result.

2.3
2.3.1

H alloysite Nanotubes

General Information and Structure
Halloysite nanotubes (HNTs) are naturally occurred alumino-silicate clay, and can

be mined from natural deposits in many countries like America, Brazil, China, France,
South Korea and Turkey [17]. They have a chem ically sim ilar com position as kaolinite
A l 2 Si 2 0 5 ( 0 H)- 4 nH 2

0

but with a difference being they have a hollow tubular structure.

HNTs are formed by multiple bilayers o f silicon dioxide and alum inum oxide. Most
com mercially available HNTs share a typical three-dim ension structure: the inner
diam eter is between 10 and 20 nm, the external diam eter ranges from 50 to 100 nm, and
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the length o f these tubes varies from 500 to 2000 nm [18]. Their wall is com posed o f 10
to 15 bilayers o f aluminum and silicon oxide [ 18]. These structural features render
halloysite a potential for drug delivery.
2.3.2

Current Application
Recently, halloysite nanotubes have attracted more and more researchers’

attention, and many papers have been published to report their achievem ents. In
Ravindra’s review paper [19], some advantages o f applying halloysite nanotubes were
pointed out, such as (1) natural, nontoxic, biocompatible; (2) fine particle size, high
surface area and superb dispersion; (3) high cation exchange capacity; (4) maintains
uniform, sustained release rates and no initial overdose; (5) capable o f prohibiting release
unless triggered and tunable release rates; (6) protects active agent within its lumen
during harsh material processing; (7) capable o f loading multiple active agents
simultaneously; (8) reduces the volum e o f costly active agents; (9) im plem entable in
many forms such as powders, creams, gels, lotions and sprays; (10) high aspect ratio,
high porosity and non-swelling; (11) superior loading rates to other carriers, fast
adsorption rate and high adsorption capacity; (12) regeneration ability and increased
efficacy. Because o f these versatile properties, HNTs can be used in many biological and
non-biological applications. In another paper, Rawtani and Agrawal [20] introduced
multifarious applications o f halloysite nanotubes, like corrosion prevention, thermal
resistance, fillers for various nanocom posites, cellular response, polym erization reactions,
drug delivery, im mobilization matrixes, and remediation.
In this dissertation, we will explore the potential o f HNTs in the field o f drug
delivery.
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2.4
2.4.1

Layer-by-Layer Assem bly

Definition and Developmental History
Layer-by-layer (LbL) assembly is defined as the use o f oppositely charged

materials with wash steps on a charged surface to build controlled architecture o f a
multilayer polym er film (Figure 2-2).

Activated
Substrate (S)

Repeated

Polyelectrolyte I

IS

Washing
Solution

Polyelectrolyte II

Multilayer
Assembly

Figure 2-2: An exam ple o f layer-by-layer process through immersion.

This can be accomplished by using many techniques such as immersion, spin,
spray, electrom agnetism , or fluidics as reviewed by Richardson et al [21 ]. The first
im plem entation o f this technique is attributed to Kirkland and Her, who carried it out
using microparticles in 1966 [22], Later this method was revitalized by Gero Decher
because o f the discovery o f its applicability to a wide range o f polyelectrolytes (PEs)
[23].
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2.4.2

M echanism
By definition, one may believe LbL multilayer build-up results solely from

electrostatic attraction. Actually, many other attractive forces are also involved
cooperatively; this is typical for high-m olecular weight building blocks, while
electrostatic repulsion provides self-limitation o f the absorption o f individual layers. This
involvement and interactions o f multiple forces make it possible to extend the LbL
technique to similarly charged polymers, hydrogen-bonded films [24], nanoparticles [25],
hydrophobic solvents [26], and other unusual systems [27], With improvement in
techniques, the deposition and wash steps can be performed in many different ways
including dip coating, spin-coating, spray-coating, flow based and electro-m agnetic
techniques [21 ].The methods used to prepare the multilayer can distinctly impact the
properties o f the products and allow their applications in various fields.
2.4.3

Advantages and Applications
The LbL technique offers several advantages over other thin film deposition

methods, such as (1) the process is simple and can be inexpensive; (2) a wide range o f
materials like polyions, metals, ceramics, nanoparticles, and biological molecules can be
applied in LbL; (3) a high degree o f control over the structure and thickness o f the
multilayer films; (4) a resolution o f 1 nm by the fact that each bilayer can be as thin as 1
nm. Because o f these properties, LbL has been used inmany applications [21]including
corrosion control, biomedical applications [28], ultrastrong m aterials [29], and many
more [30],
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2.5
2.5.1

Osteosarcom a

Epidemiology
It is estimated by the American Cancer Society that there are about 800 new cases

o f osteosarcom a every year in the United States. However, osteosarcom a is the most
com m on primary malignancy o f bone in children and adolescents [31 ]. It usually occurs
in the metaphysis o f long bones like the distal femur, proxim al tibia, and proximal
humerus during the second decade o f life. A nother small peak lies in between 60 to 80
years [32]. Overall, it has a moderate incidence rate, with 10 to 26 new cases per million
w orldwide each year [33].
2.5.2

Treatment and Prognosis
Since first being introduced by Boyer in 1805 [34], osteosarcom a has been

recognized for more than 200 years. However, the progress in prevention, diagnosis, and
treatm ent o f this tum or is still very limited. It is pointed out by the American Cancer
Society that there is no way to protect against osteosarcom a, and there are no special tests
to find this tum or in people without symptoms or strong risk factors. The best way is to
come to a doctor when any symptom o f this disease is noticed. W hat’s worse, pulmonary
microm etastasis could occur in at least 80% o f patients at diagnosis [35], These
metastases could not be found through conventional image tests. They can continue their
growth and spread 8 to 12 months after the surgical removal o f the prim ary tum or mass,
and becom e the main cause o f patients’ death within 12 to 24 months o f their appearance
[35]. The current standard treatm ent options include surgery, chemotherapy, and
radiation. Surgical intervention can remove all the detectable tum or mass, while
chem otherapeutics can kill the invisible micrometastasis around the whole body.
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Radiation is applied when patients cannot bear the severe side reactions o f the surgery
and chem otherapeutics. In most cases, an effective treatment result requires the
com bination o f both surgery and chem otherapeutics.
2.5.3

Current Challenge and Novel Approaches
The 5-year survival rate in osteosarcom a in the first half o f the 20lh century was

less than 20% [36].These patients were treated mainly with limb am putation and most o f
them died o f lung m etastasis [37]. In the 1970s, the application o f multichem otherapeutics, together with the gradually improved surgical techniques, helped to
improve the 5-year survival rate to around 60% in localized osteosarcom a (Figure 2-3)
[31].

5-year overall survival (%)
80
60
40
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0
1960s 1970s 1980s 1990s 2000s

Figure 2-3: Five-year overall survival o f localized osteosarcom a [31].

By contrast, the long-term survival o f patients with metastatic osteosarcom a still
remains at 25-30% [56-58]. The main chem otherapeutic agents used for metastatic
osteosarcom a have not changed much during the past decades [38]. Therefore, new
chem otherapeutic agents, technologies, and strategies are urgently needed to improve the
outcom e o f treatm ent for patients with osteosarcoma.
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2.6
2.6.1

Surgical Site Infection

Epidemiology
Surgical site infection (SSI) is a com mon healthcare-associated infection (HCA1),

which is estimated to account for 16% o f the total HCAI [39], In the United States,
approxim ately five million cases o f SSI occur every year, leading to an average o f 7.3
extra days in the hospital, and over 1.6 billion dollars o f additional hospital charges [40].
Some studies showed that around 5% o f all surgical operations were carried out with
com plications o f infection in hospitals in developed countries [41 ]. The situation in
developing countries is significantly worse, and some studies pointed out that the
infection rate may be twenty times higher than that in developed countries [42]. In a
word, SSI has become a serious cause o f morbidity, em otional stress, and financial cost
to the affected patients and health care institutions [43].
2.6.2

Prevention
A good understanding o f the SSI can be o f great assistance while a full clinical

assessm ent is required to identify risk factors followed by m easures to modify these
factors. The Departm ent o f Health (2007) and NICE (2013) recom mend some measures
[39] as follows:
1) Patients should stop smoking at least four weeks before surgery.
2) Pre-operative showering to reduce bacterial load on the skin
3) Antibiotic prophylaxis
4) Hair removal when required
5) Blood glucose should be controlled below 11 mmol/L
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6) Body temperature should be maintained above 36 °C within the perioperative period
to prevent vasoconstriction
7) Skin and hands preparation o f those present in the operating room
8) SSI surveillance should be completed.
In daily routine, the application o f antibiotics is an indispensable part o f the
treatment o f SSI. Efficient agents with fewer side reactions are always needed. Compared
to conventional treatment, new nanotechnology-based drug delivery systems may offer
some other options to patients and physicians.

2.7

Surgical Sutures

Sutures are routinely used in surgeries for the fixation o f tissue. Since they are in
direct contact with the wound, they have excellent potential to be used for local delivery
o f active molecules or cells to improve wound healing. In one recent study, adiposederived stem cells were filled into surgical sutures to secrete cytokines and promote
wound healing [44]. In another paper, an anti-infective coating o f surgical sutures were
developed with a combination o f antiseptics and fatty acids [45]. An in vitro study was
carried out and the result showed that a sustained release was observed, and
Staphylococcus aureus could be efficiently killed. However, there are limited papers
about using sutures as a carrier to deliver active molecules and cells to target sites. Plenty
o f room is left for research regarding effective use o f sutures for drug delivery.

CH A PTER 3
M E T H O D S AN D IN STR U M E N TA TIO N FOR EX PER IM EN TA TIO N
A N D ANALYSIS

3.1

Benchtop Vacuum Pump

Vacuum loading, as one method to be tested, was used to load drug m olecules
into halloysite nanotubes. Figure 3-1 shows the equipment required for the drug loading
process. The drug solution was made at controlled concentration. Then halloysite powder
was added into the solution, followed by full vortex to mix the suspension completely.
After that, the suspension was placed under vacuum (-25 in Hg) for 30 minutes. Air
bubbles were observed, which may suggest the solution with drug m olecules was
replenished inside the nanotubes. When no air bubbles com e out, the process was stopped
and the suspension was stirred completely. Then the vacuum loading was restarted. This
process was repeated three times. The final suspension was centrifuged, and the
supernatant was collected for absorbance measurement, by which the am ount o f loaded
drug could be calculated indirectly. The sediment was air-dried at room temperature, and
crushed into fine powder for later use.
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Figure 3-1: Vacuum pump and ja r for vacuum loading process.

3.2

Ultraviolet Visible Spectroscopy

Ultraviolet visible spectroscopy was used to measure the absorbance o f sample
solution that contains target drug molecules. Figure 3-2 shows the Nanodrop 2000c that
was used in the absorbance measurement. A standard calibration curve should be built
first through measuring several absorbance values o f target solutions with known
concentrations. Then a linear relationship could be built between the absorbance value
and concentration o f drug solution. By com parison with the standard curve, the
concentration o f the test solution can be calculated. This method was used in the release
studies where the released methotrexate and nitrofurantoin from the HNTs based drug
delivery system could be calculated.
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*<gn yotif narno when you use the Nanodr&p.

Figure 3-2: N anodrop 2000c was used for UV-Vis absorbance measurement.

3.3

Scanning Electron M icroscope

Figure 3-3 shows the scanning electron microscope (SEM ) Hitachi S-4800 used
in this project. It uses an electron beam to collect sample information and form images.
The electron beam is produced from an electron gun at the top o f the microscope. It
passes through the electrom agnetic fields and lenses to focus on the sample. Once the
sample receives the beam, it will em it X-rays and electrons that are collected by detectors
as signals. These signals are then used to form images on the m onitor screen. In this
dissertation, the SEM was used to exam ine morphology o f halloysite nanotubes and
halloysite/drug com posites.
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Figure 3-3: Scanning electron m icroscope was used to image visual changes o f
halloysite particles.

3.4

Inverted System M icroscope

Figure 3-4 shows the inverted microscope system o f Olympus 1X51 that was
designed for practical convenience and cost-effective performance for live cell study, in
vitro fertilization and other cellular injection applications. In this dissertation, a live/dead
kit was used to test the cytotoxicity o f halloysite-based com posites to osteosarcom a cells.
The Olym pus 1X51 was used to record the cellular response on the exposure o f test
nanoparticles.
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Figure 3-4: Inverted system microscope (O LY M PU S 1X51).

3.5

M icroplate R eader LT-4000

M icroplate readers are widely used in research, drug discovery, bioassay
validation, quality control and m anufacturing processes in the pharmaceutical and
biotechnological industries and in academic organizations. In this dissertation, a kit called
“CellTiter 96 Aqueous One Solution Reagent” (Invitrogen, Carlsbad, CA) was used to
test the response o f osteosarcom a cells to the released m ethotrexate from the HNTs based
drug delivery system. Figure 3-5 shows the m icroplate reader LT-4000 (Phenix Systems,
La Jolla, CA) used to read the results.

Figure 3-5: M icroplate reader LT-4000. A 96-well plate was used for the assay.

3.6

Thermo Scientific GENESYS 20

The Thermo Scientific GENESYS 20 (Houston, TX) (Figure 3-6) is a low-cost,
easy-to-use, and reliable visible spectrophotom eter designed for routine laboratories. In
this dissertation, it was used to test the optical density (OD 600 nm) o f the test bacteria,
which is directly related to cellular density. In this way, the effect o f the released drug
could be indirectly reflected via the values.

Figure 3-6: Therm o Scientific GENESYS 20.

C H A PTER 4
FA BRICATIO N M E T H O D S O F LOADING H ALLO YSITE
N A N O TU BES W ITH DRUGS

4.1
4.1.1

Introduction

Background
Ideally, an agent should have content efficacy o f the desired biological function

with few unexpected side effects. However, most currently available agents in the
pharmaceutical market have more or less side effects, and their efficacy becomes lower
and lower because o f drug tolerance from long term use. Especially in the treatment o f
cancer, which is still the most com mon cause o f mortality in humans, huge am ounts o f
chem otherapeutics are used to eliminate malignant cells. M eanwhile, normal cells and
tissues are also attacked, and patients suffer from all kinds o f side effects, which can
equally threaten their lives. Therefore, novel agents, technologies, and strategies are
needed to improve medical treatment for patients.
4.1.2

Drug Delivery
It is currently estimated to take a decade and cost over 120 million dollars to bring

a new drug through discovery, clinical testing, development, and regulatory approval
[46]. Another strategy is to improve the safety and efficacy o f current drugs by delivering
drugs at a controlled rate, slow and targeted delivery. Compared to conventional drug
adm inistration methods, the newly formed and nanotechnology-based drug delivery
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systems have several advantages in their inherent ability to overcom e solubility and
stability issues, localize drug delivery, and diagnose via in vivo image [1 ]. Theoretically,
these systems can improve the stability, absorption, and therapeutic concentration o f
drugs within the target tissue. They can also provide a sustained or controlled release at
the target site. In the pharmaceutical industry, the research on drug delivery has become a
strategy tool to expand drug markets through repackaging classic drugs in new delivery
technologies. It is estim ated that about 13% o f the currently global pharmaceutical
m arket is related to the sale o f products based on drug delivery systems [3].
A ccording to the mechanism o f how drugs are sent to the target sites, drug
delivery systems can be divided into two types, active and passive delivery. In the active
approach, biorecognition molecules are attached to the surface o f the nanovehicles to
target specific biom arkers overexpressed by cells or tissues. In the passive approach, the
goal is to facilitate deposition o f nanocarriers within target sites, where some distinctive
characteristics are present only in the target sites rather than normally healthy tissues,
fak e cancer as an exam ple, the phenom enon o f enhanced permeability and retention is
utilized to facilitate deposition o f nanoparticles loaded with chem otherapeutics within the
tum or microenvironm ent. Although active targeting delivery is an ultimately ideal model,
its transm ission from theory to practice and from laboratory to clinical practice did not
occur as smoothly as people expected. Compared to passive delivery, the requirement for
active targeting is more rigorous such as higher exclusivity and longer stability in the
blood circulation. Therefore, most o f the currently available drug delivery system s belong
to the passive category. In this project, HNTs based drug delivery systems were built via
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three different methods. These methods were com pared through their performance in
both loading and release processes.
4.1.3

Hallovsite Nanotubes
Halloysite is a naturally occurring alum ino-silicate clay and can be mined from

natural deposits in many countries such as America, Brazil, China, France, Japan, South
Korea and Turkey [17]. It has a sim ilar chemical com position with kaolin, but differs in
having a hollow tubular structure. M ost o f com m ercially available HNTs share a typical
three dim ension structure: the inner diam eter is between 10 and 20 nm, the external
diam eter ranges from 50 to 100 nm, and the length o f these tubes varies from 500 to 2000
nm [18]. Their wall is com posed o f 10 to 15 bilayers o f alum inum and silicon oxide [18].
They have a huge surface area around 65 m 2/g and a big pore volum e o f 1.25 ml/g [19],
All o f the above characteristics make HNTs a good alternative for drug delivery. In this
chapter, we will discuss some com m on fabrication methods used for drug loading with
HNTs, to show the potential o f using HNTs in drug delivery.

4.2
4.2.1

M aterials and M ethods

M aterials
Halloysite nanoclay, m ethotrexate, sodium hydroxide solution (1 mol/1),

hydrochloric acid solution, polyvinylpyrrolidone (M olecular W eig h t-1,3000,000; 1
mg/ml in DI w ater), and poly(acrylic acid) solution ( M olecular W eight-250,000, 3
ml/100 ml in DI water) were obtained from Sigma Aldrich, St. Louis MO.
4.2.2

Standard Calibration Curve and Light Sensitivity Test
As it is said in the product instruction that m ethotrexate (M TX) is sensitive to

light, the impact o f light exposure

on M TX needs to be exam ined first.A premade MTX
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solution with known concentration (1 mg/ml, pH =l 1) was kept without light protection in
a regular laboratory environment. Samples o f the MTX solution were collected and
measured by UV-Vis every 24 hours for one week. The values were com pared with that
o f the original MTX solution, and results were analyzed with one-way ANOVA (IBM
SPSS 22.0). To establish a standard calibration curve for the relationship between MTX
concentration and absorbance value, several MTX solutions with different known
concentrations were used. Then, the standard calibration curve for MTX was made from
Excel.
4.2.3

Fabrication Methods
Three fabrication m ethods were used in this project, and they were physical

adsorption, vacuum loading, and layer-by-layer (LbL) coating. The detailed process was
described as follows.
4.2.3.1

Physical Adsorption
One hundred milligram HNTs powders were immersed into 1 ml MTX solution

with controlled concentration at 1 mg/ml. A metal stir bar was added to keep stirring the
suspension for 24 hours, which may help increase the contact between HNTs and M I X
molecules. After that, the suspension was centrifuged and the supernatant was collected
for UV-Vis absorbance measurement. The sedim ent was air-dried under regular room
temperature, and was then crushed into fine pow ders for later use.
4.2.3.2

Vacuum Loading
One hundred milligram HNTs powders were immersed into 1 ml MTX solution

with controlled concentration at 1 mg/ml. Then the suspension was placed into a ja r that
was connected with a vacuum pump. A metal stir bar was added to keep stirring the
suspension while loading, which may help increase the contact between HNTs and MTX
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molecules. Once the negative pressure inside the ja r reached the pump limit (-25 in Hg),
the vacuum pump was turned o ff and the ja r was sealed. After 24 hours, the ja r was
opened and the suspension was centrifuged. The supernatant was collected for UV-Vis
absorbance measurement, and the sediment was air-dried under regular room temperature
as well as crushed into fine powders for later use. To avoid potential loss o f MTX
molecules from HNTs, the wash step was not included. Theoretically, the HNT/M TX
com posite was a combinational result from physical adsorption and vacuum loading.
Through com parison with the result o f physical adsorption, the pure am ount o f MTX
loaded inside the lumen o f HNTs could be indirectly obtained.
4.2.3.3

Laver-by-Laver Coating
As pH and the number o f coated bilayers o f polymers (PVP/PAA) may have an

impact on the drug loading property, different pH (3, 5, and 7) with different num bers o f
bilayers (3, 6, and 9) were used for LbL coating. To make the whole process simple, the
HNT/polym er composite was premade first. One gram HNT powders were immersed into
30 ml Polyvinylpyrrolidone (PVP) solution (0.1 mg/ml). Then the suspension was kept
being shaken for 15 minutes and then centrifuged and the supernatant was removed.
Deionized (DI) w ater was used to wash the sediment for 5 minutes, and was removed
after centrifuge. The same procedure was repeated with poly(acrylic acid) (PAA) solution
(0.1 mg/ml) to build the second layer. In this way, one bilayer was completed. The
HNT/polym er com posites were made according to the predetermined groups. Then, 100
mg o f the HNT/polym er composites were immersed into 1 ml MTX solution with
controlled concentration at 1 mg/ml and controlled pH correspondingly. All the
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supernatants were collected for U V-Vis absorbance measurement, and the sedim ents
were air-dried and crushed into fine powders for later use.
4.2.4

SEM Scanning
The samples including HNTs, HNT/M TX com posite, and HNT/polymers/M TX

com posite were examined by SEM for any sign o f visible change.
4.2.5

Drug Release Test
HNT/M TX or HNT/polymer/M TX com posites (25 mg/sample) were immersed

into 5 ml DI water, and the suspensions were placed on a shaker kept being shaken for 10
minutes. Then the suspensions were centrifuged, the supernatants were collected for UVVis absorbance measurement, and 5 ml fresh DI water was replenished for continuous
release. The process was repeated until only slight release o f MTX could be detected in
the supernatant. Then, sodium hydroxide w ater (pH =l 1) was used subsequently to trigger
extra release.

4.3
4.3.1

Results and

Discussion

Standard Calibration Curve
As the Nanodrop 2000c only has reliable accuracy when the absorbance value lies

between 0 and 1, samples with high concentrations were approximately diluted before
absorbance measurement. For the standard calibration curve, the results are shown in
Table 4-1 and Figure 4-1. The linear relation between MTX concentration and
absorbance value is strong and reliable within the absorbance value range between 0 and
1, which can be used to calculate the concentrations o f MTX sample solutions.
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Table 4-1: S ta n d ard ca lib ra tio n c u rv e fo r M T X (w a v e le n g th : 3 0 0 nm ).
Concentration

2

4

6

8

10

12

14

16

18

20

.101

.203

.302

.401

.494

.586

.681

.774

.865

.956

(ug/ml)
Absorbance
Value
Standard

y = 0.0 47x + 0.015 ( I = 0.999, y-absorbance va ue, x-MTX
concen tration (ug/ml ))

Curve

Linear Relationship Between MTX Concentration and
Absorbance

|

y = 0.047x + 0.015
R2 = 0.999

0.8

loo
1 0.4

<0,
0

5

10

15

20

25

Concentration (ug/ml)

Figure 4-1: Standard calibration curve for M TX made with Excel 2007.

4.3.2

Light Sensitivity Test o f MTX
Table 4-2 and Figure 4-2 show the results o f the light sensitivity test o f MTX.

SPSS (22.0) was applied to analyze whether a significant change occurred during a 7-day
period o f light sensitivity test. A Shapiro-W ilk’s test (P>.05) showed that the UV-Vis
absorbance values were approxim ately normally distributed for all o f the samples, and a
Levene’s test verified the equality o f variances in the samples (homogeneity o f variance)
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(P>.05). Then, the one-way ANOVA test (P>.05) showed that there was no significant
difference am ong all these groups, which means the impact o f light exposure on the MTX
could be ignored during a seven day period.

Table 4-2: Light sensitivity test for MTX (wavelength: 300 nm).
UV-Vis Absorbance Value
Day-1

Day-2

Day-3

Day-4

Day-5

Day-6

Day-7

Sample 1

.526

.532

.530

.529

.536

.542

.538

Sample 2

.535

.523

.523

.522

.532

.552

.542

Sample 3

.527

.516

.527

.532

.538

.523

.544

Mean

.529

.524

.527

.528

.535

.539

.541

SD

.005

.008

.004

.005

.003

.015

.003

P Value

N/A

.967

.993

1.000

.955

.678

.437

(1) One-way A NOVA (IBM SPSS 22.0) was used to analyze the statistical difference
am ong these data.
(2) SD stands for standard deviation.
(3) All the samples o f MTX solution were diluted 100 time fold.
P value shows the result com parison with Day-0.

Light Sensitivity Test for MTX
0.56
0.55
3 0.54
0.53
I

0.52

1 0.51
«

0.5
0.49

mum
Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Time Point

Figure 4-2: Result o f light sensitivity test for M TX during a 7-day period.
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4.3.3

SEM Scanning o f HNT/M TX Com posites
As we see in the SEM images (Figure 4-3), pure HNTs showed very smooth

outside surfaces. The products from both physical adsorption and vacuum loading shared
the same appearance as the arrow pointed in Figure 4-3 (B), and a bright layer could be
seen on the outside o f HNTs. In fact, in the process o f vacuum loading, MTX molecules
could also be physically adsorbed to the wall o f HNT. In other words, physical adsorption
was partially included in vacuum loading. Figure 4-3 (C) and (D) show the images o f
H NT/polym er com posites from LbL fabrication, and a bright layer on the outside surface
could also be seen. There is an obvious limit o f the SEM that the differences in LbL
structures with different num bers o f layers could not be observed, and they may present a
sim ilar appearance with the results from physical adsorption and vacuum loading.
However, in Figure 4-3 (E) the uncoated portion o f HNT was clearly seen as the arrow
pointed, and the bright layer o f LbL structure was also clearly pointed out in Figure 4-3
(F).
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Figure

4 -3 : S E M im a g e s o f H N T s an d H N T /M T X c o m p o s ite s . ( A ) P u re H N T s p a r tic le s; ( B )

M T X a tta ch ed o n th e o u ts id e su r fa c e o f H N T s; (C ) and ( D ) s h o w c lu m p e d H N T /p o ly m e r
c o m p o s ite fro m L b L fa b r ic a tio n ; ( E ) an d (F ) L b L stru ctu re w a s b u ilt o n th e o u ts id e su r fa c e .
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4.3.4

Fabrication o f HNT/MTX Composites
Three m ethods were used to fabricate the HNT/M TX com posites, and they were

physical adsorption, vacuum loading and LbL coating. A general statistical description o f
the fabrication results is shown in Table 4-3.

Table 4-3: MTX loading within HNTs or HNTs/polymer composites.
H N T s /P o ly m e r

M T X to

M T X lo a d ed

E ffic ie n c y

(mg)

lo a d (u g )

(u g )

(% )

P h y s ic a l A d so r p tio n (P A )

1 0 0 4 0 .2

1 0 4 7 .6

5 3 0 .9 6 ± 3 .4 0

5 0 .7 0 4 0 .3 0

V a c u u m L o a d in g ( V L )

1 0 0 ± 0 .2

1 0 4 7 .6

5 1 5 .2 8 ± l 1 .0 2

4 9 .2 0 4 1 .0 4

L bL

3 b ila y e r s ( 3 —3 )

1 0 0 ± 0 .2

1 0 4 6 .5

9 2 8 .5 5 4 4 .0 5

8 8 .7 3 4 0 .4 0

C o a tin g

6 b ila y e r s ( 3 —6 )

1 0 0 4 0 .2

1 0 4 6 .5

9 7 9 .0 4 ± 0 .7 7

9 3 .5 3 4 0 .0 6

pH =3

9 bi la y e r s ( 3 —9 )

1 0 0 ± 0 .2

1 0 4 6 .5

9 9 6 .7 7 4 0 .9 6

9 5 .2 3 4 0 .0 6

L bL

3 b ila y e r s ( 5 - 3 )

1 0 0 4 0 .2

1 0 4 6 .5

7 5 2 .0 2 ± 2 .9 8

7 1 .9 0 4 0 .3 0

C o a tin g

6 b ila y e r s ( 5 - 6 )

10 0 ± 0 .2

1 0 4 6 .5

7 8 9 .3 3 4 0 .8 9

7 5 .4 3 4 0 .0 6

pH =5

9 b ila y e r s ( 5 —9 )

1 0 0 4 0 .2

1 0 4 6 .5

7 9 6 .4 2 4 2 .8 3

7 6 .1 0 4 0 .2 6

1 0 4 6 .5

4 7 6 .8 4 4 4 .3 7

4 5 .5 7 4 0 .4 2

L bL

3 b ila y e r s ( 7 —3 )

10 0 ± 0 .2

C o a tin g

6 b ila y e r s ( 7 —6 )

1 0 0 4 0 .2

1 0 4 6 .5

4 8 7 .0 6 4 1 0 .2 6

4 6 .5 7 4 1 .0 1

pH =7

9 b ila y e r s ( 7 —9 )

10 0 ± 0 .2

1 0 4 6 .5

5 1 0 .6 0 4 3 .5 4

4 8 .8 0 4 0 .3 6

In stru ctio n : 1. T h er e w e r e 3 s a m p le s in e a c h g ro u p .

In each test group, a certain am ount o f MTX was successfully loaded within
HNTs or H NT/polym er composites. Groups o f physical adsorption and vacuum loading
had a sim ilar result, which was also close to the group o f LbL coated under pH 7, but
significantly lower than those coated under pH 5 and pH 3. Among all the groups, the one
coated with nine bilayers under pH 3 had the highest loading o f MTX, while the one with
three bilayers under pH 7 was the lowest (Figure 4-4).
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MTX Loading Efficiency
100. 00 %
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7 -3

7 -6

7 -9

F igu re 4-4: MTX loading efficiencies among all test groups.

As a nanocontainer, HNTs have a natural lumen which can be used to load small
molecules. They also have a huge surface area o f 65 m /g and a big pore volume o f 1.25
mL/g [19], and can physically adsorb m olecules on the surface or trap them in the pores
inside their structure. Therefore, a certain am ount o f MTX could be adsorbed physically
within HNTs.
The vacuum loading procedure used in this project was, in fact, a com bination o f
physical adsorption on the outside surface and vacuum loading inside the lumen. In
practice, it is impossible to send MTX molecules into the lumen with no contact between
MTX m olecules and the outside surface o f HNTs. Theoretically, the result o f vacuum
loading should be higher than that o f physical adsorption. However, the results in both
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groups were alm ost the same. One possible explanation is the amount o f MTX loaded
inside HNTs lumen could be statistically ignored. Or MTX molecules could not be
loaded within the lumen.
The LbL structure built on the outside surface o f HNTs obviously increased the
surface area and the porosity volume o f the nanoparticle, which can be utilized to attach
more MTX molecules. As seen in the results, LbL structures with different numbers o f
layers under different pH did impact the loading ability o f MTX. It suggested that lower
pH and more layers could help increase the capacity o f MTX loading. Still, statistical
analysis is required to make a firm conclusion.
4.3.5

Statistical Characteristics o f Samples
Before the statistical com parison o f the three methods, it is necessary to figure out

the impact o f LbL layers and pH on the H N Ts’ fabrication within the LbL groups, and to
select the best com bination o f LbL structure and pH. Table 4-4 shows the statistical
analysis o f the difference o f MTX loading with different numbers o f LbL layers when pH
was controlled. The result o f MTX loading within the H NT/polym er com posites was
used as the param eter for comparison. A Shapiro-W ilk’s test (P>.05) showed that the
results o f M TX loading were approxim ately normally distributed for all o f the samples,
and a Levene’s test verified the equality o f variances in the samples (homogeneity o f
variance) (P>.05). Then, one-way ANOVA with Post Hoc test was applied for the
analysis (Table 4-4).
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Table 4-4: S ta tistica l a n a ly sis o f th e im p a c t o f L bL lay ers o n M T X lo ad in g .

O n e-w ay A N O V A

pH=3

pH=5

pH =7

.000

.0 0 0

.002

P V alue
Post H oc T est within Each G roups
pH=3

3

pH =7

pH=5

3

6

9

3

6

9

3

6

9

bi layers

bilayers

bilayers

bilayers

bilayers

bilayers

bi layers

bilayers

bi layers

N /A

.0 0 0

.0 0 0

N /A

.000

.000

N /A

.232

.002

.000

N /A

.0 0 0

.000

N /A

.027

.232

N /A

.012

.0 0 0

.0 0 0

N /A

.000

.027

N /A

.002

.012

N /A

bi layers
6
bi layers
9
bi layers

In the groups o f pH 3 and pH 5, the num ber o f layers did play a role in the
perform ance o f MTX loading. Given the results o f MTX loading in Table 4-3. a
hypothesis could be made that more layers can help increase the MTX loading under pH
o f 3 and 5. In the groups o f pH 7, there was no statistical difference between groups o f
three bilayers and six bilayers. However, both o f them were significantly different from
groups o f nine bilayers. Therefore, the trend that more layers could increase loaded MTX
under pH 7 was not as strong as that under pH 3 and 5.
On the other hand, when the number o f layers was controlled, the impact o f pH on
the M TX loading was shown in T able 4-5. Similarly, a Shapiro-W ilk’s test (P>.05)
showed that the results o f M TX loading were approxim ately normally distributed for all
o f the samples, and a Levene’s test verified the equality o f variances in the samples
(hom ogeneity o f variance) (P>.05). Then, one-way ANOVA with Post Hoc test was
applied for the analysis (Table 4-5).
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Table 4 -5 : S ta tistic a l a n a ly sis o f th e im p act o f pH o n M T X lo ad in g .
3 bilayers

6 bi layers

9 bilayers

.000

.000

.000

One-way ANOVA
P Value

Post Hoc Test w ithin Each Groups
3 bilayers

6 bilayers

9 bilayers

pH 3

pH 5

pH 7

pH 3

pH 5

pH 7

pH 3

pH 5

pH 7

pH 3

N/A

.000

.000

N/A

.000

.000

N/A

.000

.000

pH 5

.000

N/A

.000

.000

N/A

.000

.000

N/A

.000

pH 7

.000

.000

N/A

.000

.000

N/A

.000

.000

N/A

Obviously, pH made a significant difference in each o f the groups, which means
lower pH helped increase MTX loading in all test LbL coating groups. Based on the
above results, the group with nine bilayers under pH 3 had the highest MTX loading
within the LbL coating groups, which was also much higher than both o f the groups o f
physical adsorption and vacuum loading.
An independent samples test was done between the groups o f physical adsorption
and vacuum loading, and there was no significant difference between them. Some
possible explanations could be (1) the negative vacuum pressure (-25 in Hg in this
project) might not be strong enough under laboratory conditions; (2) the m olecular size o f
MTX is bigger than the inner diam eter o f HNTs lumen. W hen com pared with the LbL
coating fabrication, neither physical adsorption nor vacuum loading had a better
performance in MTX loading.
4.3.6

Factors Affect the Drug Loading Process
In all o f the fabrication m ethods used in this project, no chemical reaction

occurred between MTX and HNTs or H NT/polym er composites. HNTs have a natural
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tubular structure inside where small m olecules could be stored. They also have a huge
surface area and porosity volume that could be utilized to adsorb or trap target molecules.
The LbL structure built on the outside surface can further increase the surface area and
pore volume, which accounts for the higher capacity o f MTX loading. Theoretically,
unlimited layers could be added continuously, which may suggest ideal capacity for drug
loading. However, abundant clumps o f H NT/polym er com posites (Figure 4-3 C and D)
formed during the LbL coating process, and the num ber o f layers was greatly limited.
The pH could indirectly affect the capacity o f M TX loading in HNT/polym er
through its important role in the LbL structure. As seen in the polyelectrolyte pair o f PVP
and PAA, a lower pH could help increase the MTX loading.
Some other factors like the drug solubility, size, and charge also have some
influence on the loading process with the HNTs based drug delivery system. Obviously, a
higher concentration o f loading solution could have more MTX attached or trapped
within HNTs or HNT/polym er com posites when the final balance arrives.
4.3.7

Drug Release
As pH and the num ber o f layers within the LbL structure play a role in the process

o f MTX loading, groups o f samples with LbL structure were compared among
themselves. Figure 4-5, Figure 4-6, and Figure 4-7 show the results o f MTX release
where pH was controlled to show the impact o f num ber o f layers on the release.
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Figure 4-5: UV-Vis absorbance m easurem ent result o f MTX release within groups
where MTX was loaded under pH 3. DI w ater was used for the first six times, and
sodium hydroxide (pH 11) was used for the rest.
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Figure 4-6: UV-Vis absorbance m easurem ent result o f MTX release within groups
where MTX was loaded under pH 5. DI w ater was used for the first six times, and
sodium hydroxide (pH 11) was used for the rest.
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Figure 4-7: UV-Vis absorbance m easurem ent result o f MTX release within groups
where MTX was loaded under pH 7. DI w ater was used for the first six times, and
sodium hydroxide (pH 11) was used for the rest.

It is clear that when pH was controlled, the num ber o f LbL layers did not have a
significant impact on the release profile. W ithin each pH group, the results looked the
same. In all these groups, a burst release was seen the first time, and subsequent lower
and lower releases continued until the second peak o f MTX release, where sodium
hydroxide was used to trigger extra release.
Figure 4-8, Figure 4-9, and Figure 4-10 show the results o f MTX release where
LbL structure was controlled to expose the impact o f pH on the MTX release profile.
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Figure 4-8: U V-Vis absorbance m easurem ent result o f MTX release within groups
where M TX was loaded with three bilayers o f (PVP/PAA). DI w ater was used for the
first six times, and sodium hydroxide (pH 11) was used for the rest.
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Figure 4-9: U V-Vis absorbance m easurem ent result o f MTX release within groups
where MTX was loaded with six bilayers o f (PVP/PAA). DI w ater was used for the
first six times, and sodium hydroxide (pH 11) was used for the rest.
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MTX Release W ithin Groups o f 9 Bilayers

Release Tim e

Figure 4-10: UV-Vis absorbance m easurem ent result o f MTX release within groups
where MTX was loaded with nine bilayers o f (PVP/PAA). DI w ater was used for the
first six times, and sodium hydroxide (pH 11) was used for the rest.

Still, a burst release was seen the first time, and subsequent lower releases went
on until the second peak where sodium hydroxide was used for extra MTX release.
Although the shape o f the release profile in each group was the same, the groups o f pH 3
had the highest release alm ost every tim e while the groups o f pH 7 had the lowest. Unlike
the num ber o f bilayers in the LbL structure, pH showed a significant impact on the
release results, which suggests that a low er pH may help increase the release o f MTX.
Therefore, within the LbL coated HNTs groups, the one with nine bilayers under
pH 3 was selected to represent the LbL coating fabrication for com parison with the other
two methods. Figure 4-11 shows the results o f M TX release among the three fabrication
methods.
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Figure 4-11: UV-Vis absorbance m easurem ent result o f MTX release am ong groups
with different fabrication methods. DI w ater was used for the first six times, and
sodium hydroxide (pH 11) was used for the rest.

Still, the shapes o f the release profile were the same. However, the group with
LbL structure had the highest release while the other two shared the same performance.
Additionally, the ratio between test particles and water could also affect the release
profile. In this project, the ratio was controlled at 5mg/ml, and the release process was
repeated ten times.
4.3.8

Process o f Drug Release
The main factor that drives loaded M TX to be released in surrounding solution is

the concentration gradient, which is also the same mechanism used in the drug loading
process. All the dissolved MTX m olecules keep m oving around in the solution all the
time. Some moved from HNTs to surrounding solution, while others moved from
solution to HNTs, which means both the loading and releasing processes were occurring
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at the same time. However, the net moving direction o f the total m olecules was consistent
with the concentration gradient between the solution and the HNT/M TX nanoparticles.
Once a new balance was reached, the net moving stopped. When fresh DI w ater was
replaced, a new concentration gradient formed, and the net moving o f M TX m olecules
towards a lower concentration restarted, which would continue until the next balance
occurred.
The burst release o f M TX on the first time could be explained by the theory o f
concentration gradient, as it had the biggest value on the first time. When sodium
hydroxide was replenished instead o f DI water, all o f the test groups showed a second
peak o f release. The reason is the basic environm ent can increase the solubility o f MTX
in water, and increase the net movement o f MTX m olecules from HNTs to solution. It
well explains the second peak in the groups o f physical adsorption and vacuum loading.
In the groups o f LbL coating, not only did the higher pH increase the solubility o f
MTX, it also changed the LbL structure leading to more MTX m olecules releasing from
HNTs. The best evidence is the superimposed release o f MTX in the LbL coating group,
which was higher than that in both groups o f the others. Therefore, the LbL structure
could help carry more MTX m olecules than pure HNTs. In this style, the loaded MTX
m olecules would continuously be released into the surrounding environm ent, and the
period for this release process would be partially determined by the rate o f MTX
consum ption by the circumam bient tissue.

4.4

Conclusions

In this chapter, MTX was successfully loaded within HNTs or HNT/polym er
com posites through three methods including physical adsorption, vacuum loading, and

LbL. coating. HNTs coated with the LbL structure had a significantly higher ability than
the other two methods in MTX loading, and there was no statistical difference between
physical adsorption and vacuum loading in the performance o f M TX loading and
releasing, which may suggest that little or slight MTX was loaded within the HNTs
lumen. Although it has already been reported that HNTs could be used to load resveratrol
within their lumen space [47], the same method was not well applied with MTX. pH had
a very important role in the MTX loading, while the num ber o f coated layers could only
slightly increase the loaded MTX under lower pH. In the release process, a burst release
was seen in all the test groups, and subsequent low er releases continued until a second
peak occurred by the usage o f sodium hydroxide. Compared with pure HNTs, the LbL
coated HNTs had higher release o f MTX, which may show a potential o f longer release
period. Besides the properties o f HNTs or HNT/polym er com posites, the consumption
rate o f MTX by the surrounding environm ent could partially determine the length o f the
release period, too. As a natural nanom aterial, HNTs showed great potential o f loading
and releasing target molecules, and offered another option for drug delivery.

C H A PT E R 5
PO TEN TIA L A PPL IC A T IO N OF USING H A LLO Y SITE
NA N O TU BES BASED DRUG D ELIV ER Y IN TH E
T R EA TM EN T O F O ST E O SA R C O M A

5.1

Introduction

This chapter is based on my published manuscript titled "Drug C oated Clay
Nanoparticles fo r Delivery o f Chemotherapeutics, " Current Nanoscience, 2016, 12(2)
[48]. 1 am the author o f this paper, and its content is used only in my dissertation. In this
chapter, an in vitro cellular test with osteosarcom a is used to show the potential o f using
HNTs as a tool to deliver chem otherapeutics in the treatment o f cancer.
5.1.1

Halloysite Nanotubes
Halloysite nanotubes (HNTs) are naturally formed alumino-silicate clay tubules

that are chem ically similar to kaolin clay [70-72]. HNTs occur abundantly in nature and
can be readily mined and sorted, making them an econom ically viable nanomaterial [49].
HNTs are routinely used as a functional filler to improve the mechanical performance o f
cements and polym ers [74-76]. The geometrical structure and surface charges o f HNTs
make the material a viable nanocontainer for drugs, bioactive m acrom olecules, and
polymers, for sustained and extended releases [77-79].
Recently, a publication reported the application o f using HNTs to deliver
resveratrol to cancer cells [47]. Their inner luminal space was used for loading resveratrol
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and an additional coating o f poly(sodium 4-styrene-sulfonate) and poly(allylamine
hydrochloride), or protam ine salt and dextransulfate sodium salt was coated on HNTs to
slow the drug release. With a negatively charged outer surface, HNTs can be effectively
coated by sequential adsorption o f positively and negatively charged polyelectrolytes
(layer-by-layer (LbL) nano-assembly). LbL nano-assembly o f multiple polyelectrolyte
nano-film s has been shown as a potential m ultifunctional carrier system for drugs,
enzym es, and cells [80-82]. Recent studies have also shown that HNTs display noncytotoxic effects on several cell types such as mesenchymal stem cells,
fibrochondrocytes, osteoblasts and human dermal fibroblasts (up to concentrations o f .1
mg/ml) [83-84], The biocompatible and drug release properties o f HNTs make them an
ideal candidate for new drug delivery systems.
5.1.2

M ethotrexate
M ethotrexate (M TX) is com m only used in the treatment o f cancer, autoimm une

diseases, ectopic pregnancy, and for the induction o f medical abortions. Since being
discovered in the early 1970s, MTX has become one o f the four m ajor classes o f
chem otherapeutic agents with established efficacy in the treatment o f osteosarcom a [50] .
M TX is an antim etabolite and antifolate drug that inhibits dihydrofolatereductase, an
enzym e involved in cellular DNA synthesis. It is generally considered that a serum
concentration o f MTX greater than 1,000 pmol/1 administered as an infusion over four to
six hours is required for successful therapy [85-86].
5.1.3

Osteosarcoma
O steosarcom a (OSA) is the most com mon malignancy o f bone in children and

adolescents, and is characterized histologically by the production o f an extracellular
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osteoid-like matrix. It represents about 3.4% o f all childhood tum ors and 56% o f
m alignant bone tum ors [51]. Standard treatm ents include adjuvant chemotherapy,
radiotherapy, hormone or biological therapy, and if OS A is refractory, surgical ablation o f
the prim ary tum or is needed. Advancem ents in treatm ent modalities have led to increased
rates of'lim b-sparing' surgeries, but patients are still threatened with the risk o f
recurrence. Tum or recurrence is greater than 90% for the patients without clinically
diagnosed metastasis who receive surgical resection o f the prim ary m alignancy and do
not continue with adjuvant chem otherapy [50]. Surgical abscission can remove all sites o f
clinically detectable tum or mass physically and systemic chem otherapy can inhibit
microm etastasis before and/or after surgery. O ther patients with sim ilar disease
conditions who are adm inistered chem otherapeutic agents alone will suffer a 100%
probability o f local recurrence without surgical excision o f the primary tum or [52].
Significant advances have been made in the treatment o f osteosarcom a over time;
however, new treatm ent and prevention strategies are still needed.
In this chapter, we dem onstrate that polyelectrolyte coated HNTs loaded with
MTX can be easily fabricated and that M TX coated HNTs can be embedded into nylon-6.
HNT nanocom posites were tested for their cytotoxic and anti-proliferative effects against
osteosarcom a cells. HNT/M TX doped com posites were shown to alter osteosarcom a cell
morphology and behavior and inhibit cell proliferation. Data support the potential for
using doped H NT/polym er com posites as a delivery tool for chem otherapeutic agents
capable o f delivering a focal and sustained concentration o f drugs.
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5.2
5.2.1

M aterials and M ethods

Materials
Osteosarcoma cells (OC, U M R-106) were obtained from ATCC, M anassas, VA.

Halloysite nanoclay, m ethotrexate, sodium hydroxide solution (1 mol/1), hydrochloric
acid solution (pH=2), Polyvinylpyrrolidone (M olecular W eig h t-1,3000,000; 1 mg/ml in
DI water), poly(acrylic acid) solution ( M olecular W eight-250,000, 3 m l/100 ml in DI
water), nylon-6, and formic acid solution were obtained from Sigma Aldrich, St. Louis,
MO. 96-well plates and other lab plastics were purchased from M idSci, St. Louis, MO.
D ulbecco’s Phosphate Buffered Saline (DPBS), D ulbecco’s M odified E agle's M edium
(DM EM ), fetal bovine serum (FBS), Live/Dead V iability/Cytotoxicity kit and penicillinstreptomycin-amphotericin (PSA) antibiotics were obtained from Life Technologies,
Carlsbad, CA. CellTiter 96 Aqueous One solution reagent was purchased from Promega,
Madison, WI.
5.2.2

Composite Fabrication
Two hundred milligram HNTs were immersed in 1 ml o f polyvinylpyrrolidone

solution (1 mg/ml, pH=2) and mixed for ten minutes. The mixture was then centrifuged
at 13.4 xlOOO R.P.M. for three minutes and the supernatant was removed. The process
was repeated with poly-acrylic acid solution (1 mg/ml, pH=2) and the alternating o f PVP
and PAA was repeated. A total o f six layers were deposited (H NT/(PVP/PA A) 3 ). After
the sixth layer, 1 ml o f methotrexate solution (1000 pg/m l, pH=2) was added and mixed
for ten minutes, and centrifuged. The com posites were dried and crushed into fine
powder for later use. To avoid any potential loss o f MTX, the coating process ceased
after the drug layer was added. The final structure was HNT/(PVP/PAA)j/M TX (see
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Figure 5-1). The HNT/(PVP/PAA) 3 /M TX composites were also examined as a functional
filler for nylon- 6 . N ylon - 6 solution (20% w/w) was prepared by dissolving with formic
acid. HNT/(PVP/PAA)3/M TX (3% w/w) was mixed into the nylon - 6 solution
homogeneously, then poured into a 24-well plate, and was air-dried for 24 hours. The
final product was nylon - 6 loaded with HNT/(PVP/PAA) 3 /M TX. Figure 5-1 details the
coating architecture o f control and experimental groups.
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Figure 5-1: Graphic illustration depicting the assembly of the polyelectrolyte coatings and
drug infusion process on the surface of a halloysite nanotube. The assembly process begins at
top left with specific steps proceeding from left to right and top to bottom. The fabrication is
based on electrostatic interactions between all materials (Halloysite nanotubes (HNTs),
polyvinylpyrrolidone(PVP), Poly (acrylic acid) (PAA), methotrexate(MTX)). This graphic
depicts the process and is not meant to suggest the final coating structure.
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5.2.3

Scanning Electron M icroscopy
Coated HNT samples were coated with (PVP/PAA)3/M TX and imaged with a

Hitachi Field Emission Scanning Electron M icroscope. Demonstration o f the coated
HNTs and surface features were observed.
5.2.4

Drug Release Tests
First, a calibration curve was created for MTX to compare with the drug elution

profiles o f the HNT/(PVP/PAA)3/M TX composites. Three sample sets, each with 20 mg.
o f HNT/(PVP/PAA) 3 /M TX, were immersed in deionized w ater (1 ml, pH=7.0) and mixed
for ten minutes. Samples were centrifuged and the supernatants were collected for UVvis. analysis (N anodrop 2000c, ABS wavelength 300 nm). Samples were replenished
with fresh DI w ater and the process was repeated 15 more times (total time=160
minutes).
5.2.5

Cell Culture
Osteosarcoma cells were plated in 25 cm tissue culture flasks, and incubated at

37 °C under humidified 5% C 0 2 and 95% air in com plete DMEM containing 10% FBS
and 1% PSA. Subconfluent cells were passaged with 0.25% trypsin, collected by
centrifugation, suspended in com plete DMEM and cultured at a 3:1 split into 25 cm 2
tissue culture flasks. These cultures were used for viability and proliferation tests.
5.2.6

Viability and Proliferation Tests
Subconfluent osteosarcom a cells were released with 0.25% trypsin, collected by

centrifugation, re-suspended in com plete DMEM, and seeded in a 96-well plate. After 24
hours, culture wells were then washed with DPBS. The cells were next exposed to
DMEM alone, DM EM /HNT, DM EM /HN T/(PV P/PA A)3,
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D M EM /HNT/(PVP/PAA) 3 /M TX, D M EM /HNT/(PVP/PAA) 3 /nylon, and
D M EM /HN T/(PV P/PA A) 3 /M TX/nylon. The cell density was controlled at 10,000 per
well. O ther param eters included: HNT (2000 pg/ml), H N T/(PVP/PA A ) 3 (2000 pg/ml),
HNT/(PVP/PA A )3/M TX (2000 pg/ml), HNT/(PVP/PA A )3/nylon (10 mg/ml),
HNT/(PVP/PAA) 3 /M TX/nylon (10 mg/ml). After 72 hours, the Live/Dead
viability/cytotoxicity kit was applied for viability test, and the CellTiter 96 aqueous
solution reagent was applied for proliferation test.

5.3
5.3.1

Experim ental Results

Drug Coating
Under SEM microscopy uncoated HNTs displayed a tubular structure with

smooth surfaces while coated HNTs (+/- MTX) have a thin coating as seen in Figure 5-2.
HNTs often stacked together, with small clusters and aggregated clumps that may have
resulted due to the drying preparation step required for electron microscopy.
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Figure 5-2: Scanning electron microscopic images of uncoated HNTs (A) and HNTs that have
been coated HNT/(PVP/PAA)3/MTXXB), (C), and (D). Coated HNTs are visible in Figure (B)
and (C) (arrows). Clusters of coated HNTs were seen in figure (C) and larger aggregate clumps
(D) were observed and may have formed during processing for SEM.

Visual confirm ation that coated and drug coated HNTs were successfully mixed
into nylon - 6 is clearly visible in Figure 5-3. There were noticeable changes in contrast
and color o f the coated HNT/nylon com posites after being air-dried overnight, the formic
acid evaporated com pletely leaving only the complex o f HNT/(PVP/PAA) 3 /nyIon and
H N T/(PV P/PA A ) 3 /M TX/nylon (Figure 5-3). Compared to H NT/(PVP/PAA) 3 /nylon, the
yellow color o f the HNT/(PVP/PA A ) 3 /M TX/nylon suggests that MTX had been released.
Results from the Live/Dead cytotoxicity and cell proliferation tests support this
observation.
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Figure 5-3:

T im e - la p s e im a g e s o f th e a ir-d ried c o a te d H N T c o m p o s it e s ( A , C ).

H N T /(P V P /P A A )3 ( w h it e d is k s ) v s . ( B , D ) H N T /(P V P /P A A )3/M T X ( y e l lo w is h tin t).N y lo n - 6
s o lu tio n (2 0 % w /w ) w a s trea ted w ith fo r m ic a c id . H N T /(P V P & P A A ) 3 and
H N T /(P V P /P A A )3/M T X (3 % w /w ) w e r e th en th o r o u g h ly m ix e d in to th e n y lo n - 6 s o lu t io n , th en
p o u re d in to a 2 4 - w e ll p la te , an d a ir -d r ie d a n d o b s e r v e d a fte r a 2 4 h o u r s p e r io d .

5.3.2

Drug Release from HNTs
During drug elution monitoring, the H N T/(PVP/PA A ) 3 /M TX sam ples showed a

burst release during the first

10

m inutes and continued with a steady release that slowly

decreased until a second release peak after 130 m inutes, with M TX released at reduced

levels through 160 m inutes (Figure 5-4). The first release may be from a layer o f drugs
positioned on the very outer surfaces o f the com posites. The second burst release may be
due to the pH o f the immersing solution, which can affect the degradation rate o f the PEs.
Also, some o f the drug m olecules may have seeped out from the porous PE structures.
The release study was term inated after 160 minutes, as very little am ount o f M TX was
being released. D1 water, with a neutral pH, was used as the elution medium during the
release test. MTX concentration gradient and the pH o f im mersing solution are presumed
to have determined the release profile o f MTX. Overall, the PE coatings appeared to have
effectively trapped MTX.
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Figure 5-4:

D ru g r e le a s e fo r M T X fro m H N T /(P V P /P A A )j/M T X in D I w a te r (p H 7 ) o v e r

160

m in u te s. T h e U V a b so r b a n c e re p r e se n ts th e c o n c e n tr a tio n o f M T X in th e sa m p le s . F ig u r e A
d is p la y s th e a m o u n t o f d r u g r e le a se d at e a c h tim e p o in t. F ig u re B s h o w s th e c u m u la tiv e r e le a se
o f a ll th e s a m p le s b y tim e p o in t.
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5.3.3

Live/Dead Cytotoxicity
Osteosarcoma cells in monolayer culture proliferated and obtained confluence within 2-3

days with little cell death observed (Figure 5-5 A-C). Osteosarcoma cells were also unaffected by
the addition of HNTs (Figure 5-5 D-F). Cells proliferated and achieved confluence comparable to
normal, untreated cells (compare Figure 5-5 B and C with Figure 5-5 E and F).

B

Figure 5-5: Cytotoxic response to HNTS. (A-C) Group 1:Osteosarcoma cell cultures with no
HNT addition. (D-F) Group 2: Osteosarcoma cells exposed to HNTs at a concentration of 2000
ug/ml). A, D = Phase contrast, B,E = Live Dead assay showing live cells (green), C, F = Dead
assay showing dead cells (red). The brown coloration in figure 5-5D is due the high
concentration of HNTs. Bar = 200 microns.

Coated HNTs (without MTX, control Group 3), HNT/(PVP/PAA), coated nanoparticles
could be seen clearly as particulate material (Figure 5-6 A). Although osteosarcoma cells were
not as confluent as seen in groups

1

and 2 , the majority of the cells were observed growing and

proliferating with few cell deaths (Figure 5-6 A-C). In MTX treated groups, the cellular response
was very different (Figure 5-6 D-F). In group 4, osteosarcoma cells exposed to HNTs with a
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(PVP/PAA)VMTX coating showed a marked reduction in cell growth as compared to controls
(Group 3). However, only a few dead cells were observed (Figure 5-6 F).

Figure 5-6: Cellular response to PE coated HNTs and HNTs coated with PEs and MTX. (A-C)
Group 3: Osteosarcoma cells were exposed to HNT/(PVP/PAAh (2000 ug/ml). (D-F) Group 4:
Osteosarcoma cells were exposed to HNT/(PVP/PAA)VMTX (2000 ug/ml). A, D = Phase
contrast, B, E = Live/Dead assay showing live cells (green), C, F = Live/Dead assay showing
dead cells (red). Bar = 200 microns.

When HNTs coated with (PVP/PA A ) 3 were embedded in nylon- 6 , results also
showed a low cytotoxic effect, as cells grew to confluence with little cell death (Figure
5-7 A-C). In contrast, cells exposed to HNT/(PVP/PAA) 3 /M TX/nylon grew but
proliferation was inhibited with only a few dead cells observed (Figure 5-7 D-F).

Figure 5-7: Cellular response to coated HNTs embedded in nylon. (A-C) Group 5:
Osteosarcoma cells were exposed to HNT/(PVP&PAA)3/nylon (10 mg/ml)). (D-F) Group 6 :
Osteosarcoma cell were exposed to HNTs/(PVP&PAA)3/MTX/nylon (10 mg/ml). A, D =
Phase contrast, B, E = Live/Dead assay showing live cells (green), C, F = Live/Dead assay
showing dead cells (red). Bar = 200 microns.

5.3.4

Cell Proliferation Assay
The result o f the cell proliferation assay is shown in Table 5-1. The values o f

Groups 1, 2 and 5 were very sim ilar suggesting that HNTs and HNT/(PVP/PA A ) 3 /nylon
did not provoke an anti-proliferative response. Groups 3, 4 and

6

showed a reduction in

cell proliferation, which can be attributed to the degraded polyelectrolyte layers (in
Groups 3 and 4) and M TX released from the drug coated HNTs com posites (in Groups 4
and 6 ).
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T ab le 5-1: Control and experimental groups and their coating architecture with results
o f the cellular proliferation assays.
Group

Treatment

Value

Control

(DMEM only)

0.290 ± 0.000

Group 1

Normal cells

1.987 ± 0 .0 7 4

Group 2

HNTs only

2.118 ± 0.154

Group 3

H N Ts/(PV P& PA A ) 3

1.114 ± 0 .0 9 7

Group 4

H NT s/(PV P& PA A )3/M TX

0.924 ± 0 .1 0 3

Group 5

HNTs/(PV P& PA A)3/ny Ion - 6

1.895 ± 0 .2 8 8

Group

6

H NTs/(PVP& PAA) 3 /M TX /nyIon - 6

1.162 ±

0 .1 2 0

Sixteen samples were used in each o f the group (except group 2 which has 14 cases as
two outliers were rem oved) for the cellular proliferation tests. The absorbance value is
directly related to the num ber o f viable cells.
As shown in Figure 5-8, when exposed to uncoated HNTs and coated HNTs (+/M TX), cellular response am ong these groups was significantly different. Compared with
the group o f normal cells, cell proliferation was higher in the group o f HNTs and stayed
the same in the group o f HNT/(PVP/PA A ) 3 /nylon, whereas it became low er in the other
groups. A significant reduction was shown in the group o f
HNT/(PVP/PAA) 3 /M TX/nylon, and a further reduction was seen in both groups o f
HNT/(PVP/PAA ) 3 and HNT/(PVP/PA A ) 3 /M TX. The result o f statistical analysis is
shown in T ab le 5-1. SPSS (22.0) was applied with one-way ANOVA, and the normality
(P>.05) and homogeneity (P=.044) were checked. Significant differences (P=.000) were
seen among the groups, and subsequent Post Hoc tests were used to show the specific
difference among the groups (Table 5-2). Overall, the pattern in cell proliferation mirrors
that observed in the cytotoxicity analyses.
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Results o f The Cellular Proliferation Assays

Figure 5-8:

S ix te e n s a m p le s w e r e u se d in e a c h g r o u p (e x c e p t G r o u p 2 w h ic h h a s 14 c a s e s a s

tw o o u tlie r s w e r e r e m o v e d ) fo r th e c e llu la r p r o lifer a tio n te s ts . T h e a b so r b a n c e v a lu e is d ir e c tly
rela ted to th e n u m b e r o f v ia b le c e lls . F rom le ft to rig h t, th e g r o u p s are: D M E M C o n tr o l, G ro u p
I (N o r m a l c e ll s ) , G ro u p 2 (H N T s ) , G r o u p 3 ( H N T /( P V P /P A A ) 3), G r o u p 4
( H N T /( P V P /P A A ) 3/M T X ), G r o u p 5 (H N T /( P V P /P A A ) 3/n y lo n ) , a n d G r o u p 6
( H N T /( P V P /P A A ) 3/M T X /n y lo n ). S ta tistic a l a n a ly s is w a s a p p lie d w ith IB M S P S S 2 2 .0 , an d th e
stars in d ic a te a s ig n ific a n t d iffe r e n c e e x is ts w h e n c o m p a r e d w ith G r o u p 1.

Table 5-2:

T e m p la te fo r in s e r tin g ta b le s.

Comparison

Significant Difference (P value)

Group 1 Vs. Group 2

P = .000

Group 1 Vs. Group 3

P = .000

Group 1 Vs. Group 4

P = .000

Group 1 Vs. Group 5

P = .803

Group 1 Vs. Group

P = .000

6

Group 3 Vs. Group 4

P = .409

Group 3 Vs. Group 5

P = .000

Group 4 Vs. Group

6

P = .000

Group 5 Vs. Group

6

P = .000

IBM SPSS (22.0) and one-way Ah OVA were used for the statistical analysis.
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5.4

Discussion

In previous papers, the luminal porosity o f HNTs has been estimated to be around
■y

0.25 ml/g, while the outside surface area o f HNTs has been shown to be about 57 m /g
[53]. It is apparent that the HNT lumen has space limits for drug loading. Attem pts have
been made to enlarge the HNT lumen to increase drug loading by acid etching, and while
increases in drug loading capacity were observed, there are limits to how much drug may
be loaded with this technique [54], The outer HNT surface provides significantly more
potential surface area for drug loading, especially if the surface has been m odified or
coatings have been applied onto (or around) the outer surface. In HNTs, silica is mainly
distributed on the outer surfaces, whereas alumina is mainly positioned on the inner
surface and edges o f the tubule. Upon exposure to water, the outer surface will have a
negative charge over a wide range o f pH (2—10), so at an appropriate pH above 2,
halloysites’ negatively charged outer surface permits sequential adsorption o f positive
and negative charged polyelectrolytes [53].
When immersed in water, PVP is positively charged [55] and PAA is negatively
charged [56]. Accordingly, we used the outer HNTs surface rather than the inner luminal
space o f HNTs to load and release MTX using a scheme for coating HNTs with
sequential layers o f positively charged PVP and negatively charged PAA [57]. In this
way, the PE coatings provide a means for controlling both the location o f the drug and
the pattern o f drug release. The data showed high concentrations o f MTX were absorbed
during the coating process, as little MTX was discem able in the acidic loading solution
(pH=2) after coating process. This supports the conclusion that the majority o f the MTX
molecules had been attached to the PE layers or trapped within the pore spaces. The two
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different burst releases seen in the UV-vis release data, suggests that the PE layers may
have become more porous during fabrication. The first burst release o f MTX may have
com e from the MTX m olecules attached to the outside surface o f the clumped material.
The second burst release might have occurred because o f slow degradation o f the PE
layers, which liberated more MTX m olecules subsequently. Another important factor to
consider is the rate o f MTX that is consum ed by the environm ent, which may affect the
length o f drug release.
Cytotoxicity assays showed that osteosarcom a cells proliferated in the presence o f
untreated HNTs and few cells died even after exposure to a very high concentration o f
HNTs (2 mg/ml). This is consistent with previous studies where halloysite nanotube
exposure had little negative impact on cell growth or functionality [83-84]. Furthermore,
HNTs coated with PVP and PAA which was further mixed within nylon - 6
(HNT/(PVP/PAA) 3 /nylon) also showed little to no cytotoxic effect. In the other groups,
HNT/(PVP/PAA)3, HNT/(PVP/PAA) 3 /M TX, and HNT/(PVP/PAA) 3 /M TX/nylon showed
little cytotoxicity, with only a few dead cells observed with the Live/Dead cytotoxicity
assay. However, their cellular proliferation was significantly reduced.
Statistical analysis showed that Group 2 (HNTs, P=.000), Group 3
(H NT/(PVP/PA A)3, P =.000), Group 4 (H NT/(PVP/PA A) 3 /M TX, P =.000), and Group

6

(H NT/(PVP/PA A) 3 /M TX/nylon, P =.000) are significantly different from Group 1
(Normal cells), which means the cell proliferation was significantly higher in Group 2
and reduced in Groups 3, 4, and

6

. In G roup 2, it seem s that HNTs had a stimulant effect

on the cells, as the mean was higher than that in G roup 1. Although there was no MTX in
G roup 3, the reduction o f cell proliferation might be caused by the interaction between
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hydrolyzed polymers and amino acids in the medium which led to a subsequent failure o f
cell proliferation. In G roup 4, besides the effect o f hydrolyzed polymers, the release o f
MTX further reduced the cell proliferation, but did not kill the cells. As there was no
difference between Groups 1 and 5 (P=.803) which means the com posites o f
H NT/(PVP/PA A ) 3 /nylon had no effect on the cells, the reduction o f cell proliferation in
Group

6

could only be explained as the release o f MTX. The same principle could be

used to explain the difference between Groups 5 and

6

(P=.000). No difference was

shown between Groups 3 and 4 (P=.409), as both hydrolyzed polymers and MTX could
only stop cell proliferation but not kill them. Group 5 was significantly different from
Group 3 (P=.000), because the nylon structure could well trap hydrolyzed polymers
which prevent their interaction with am ino acids inside the medium. But it could not
com pletely restrain the release o f MTX into the medium, which caused a limited
reduction o f cell proliferation in Group

6

when compared with Group 4 (P=.000).

In sum, morphological observations, cytotoxicity and proliferation assays support
the conclusion that MTX was released from HNT/(PVP/PAA) 3 /M TX and
HNT/(PVP/PAA) 3 /M TX/nylon com posites and subsequently altered osteosarcom a cell
m orphology and inhibited cell proliferation, which provided support for its potential use
as a drug delivery vehicle. Our drug releasing system offers other advantages, including
carrying a higher drug load as compared with using a vacuum to load drugs into the HNT
lumen. W hen drug doped HNTs are added to different polymers there is a point where
addition o f increased am ounts o f doped HNTs (to increase drug load) decreases material
properties (tensile resistance, adhesion, etc.) [94-95]. Our method has the potential to
overcom e this by placing the appropriate (required) drug-load on the surface o f the
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HNT/PEs, thus offering no challenges to material properties. Preliminary experiments
with MTX release from nylon - 6 are suggestive that this method o f drug incorporation
may also be applied to other polymers.
Current studies are directed at refining the specific PE shell structure with the
intent to increase/decrease the loading ability o f HNTs, speed up/down drug release, and
enable doping with multiple drugs. As we have shown, chem otherapeutic drugs can be
doped into H NT/polym er m ixtures such as N ylon - 6 and still retain an anti-cancer cell
effect. This offers much prom ise for the incorporation o f drug coated HNTs into a variety
o f medical grade, biocom patible synthetic polym ers and/or natural proteins for use in
anti-infective, chem otherapeutic or histiogenic catheters, gauze, sponges, and sutures.

5.5

Conclusion

Halloysite nanotubes did not provoke a cytotoxic effect on osteosarcom a cells nor
inhibit their proliferation ability up to a concentration o f 2000 ug/ml. M ethotrexate was
incorporated into a PE coating and was observed to be released from the coating.
Released MTX resulted in altered cell behavior including morphological changes in
osteosarcom a cells and a reduction in cell proliferation. After the M TX-coated HNTs
were m ixed with nylon- 6 , the releasing ability o f MTX was preserved, and the released
MTX also altered osteosarcom a cell behavior and inhibited cell proliferation. As a
nanocom posite drug delivery system, MTX coated HNTs show a potential for the
delivery o f antitum or drugs. W hile M TX was the drug used in this study, there is also a
potential for the system to incorporate other drugs. The system also has the potential to
insert drugs at different coating depths that may permit multiple, com binatorial or even
sequential release depending on coating architecture and com position.

C H A PT E R 6
PO TEN TIA L A PPL IC A T IO N O F USING H A L L O Y SIT E
NA N O TU BES BA SED SU T U R E S IN TH E PR EV EN TIO N
O F SU R G IC A L SITES IN FEC TIO N

6.1

Introduction

In this chapter, another application was used to verify the feasibility o f using
halloysite nanotubes (HNTs) based drug delivery system in the medical field. The
hypothesis was that nitrofurantoin (NFT) coated halloysite com posites could release the
drug in a sustained manner and efficiently inhibit bacterial proliferation, which showed a
potential in the prevention o f surgical site infection (SSI).
6.1.1

Surgical Site Infection
Surgical site infection is a postoperative com plication feared in surgery, and can

lead to considerable consequences for patients and high medical cost for society [96-97].
It is a com mon healthcare-associated infection (HCAI), and accounts for about 16% o f
the total HCAI [39], In the United States, approxim ately five million cases o f SSI occur
every year, leading to an average o f 7.3 extra days in hospital, and over 1. 6 billion dollars
o f additional hospital charges [40]. A prospective study from Spain [58] showed that SSI
happened to 9.02% o f the total people who underw ent surgery. Their stays were
prolonged by 14 days, and the excess hospital costs were $10,232 per patient. W hat is
worse, health costs only accounted for

10

% o f overall costs, and there was an extra
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$97,433 per person from indirect social costs. SSI has become a serious cause o f
morbidity, emotional stress, and financial cost to the affected patients and health care
institutions [43]. Appropriate strategies, technologies, and agents are needed to improve
surgical treatm ent and save unnecessary direct health costs as well as indirect social
costs.
6.1.2

Nitrofurantoin and Drug Delivery
One Italian study for epidemiology and microbiology o f surgical wound

infections included 676 patients with signs and sym ptom s indicative o f infections, and
showed com mon pathogens that included S. aureus, P. aeruginosa, E. coli, S.
epidermidis, and E. faecalis [59]. Nitrofurantoin (NFT) is an antibiotic which has been
proven effective against many bacterial pathogens including E. coli, S. aureus, and E.
faecalis [60]. Because o f low rate o f resistance, more and more attention has been
focused on NFT. N FT exerts greater effects on bacterial cells than mammalian cells, and
the developm ent o f resistance to its effects is low because o f its involvement in many
different processes important to bacterial cells. For exam ple, acquired resistance in E.
coli continues to be rare [60]. However, it also has some shortcomings, which seriously
limit its usage. The peak blood concentration o f N FT following an oral dose o f 100 mg is
less than 1 ug/ml, and tissue penetration is negligible. It can be metabolized by the liver
rapidly, and is excreted mainly in urine. Therefore, it is used mostly in urinary tract
infections. The application o f a newly formed HNTs based drug delivery system could
potentially improve this situation. Given its low tissue penetration and broad antibacterial
function in the pathogens related to surgical site infection, NTF was used as a model drug
loaded in the HNTs system and showed potential against E. coli to prevent SSI.
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6.1.3

Electrospun Nanofibers and Sutures
Because o f the rapid developm ent o f nanoscience and nanotechnology over the

past decades, there are many advances made not only in preparation and characterization
o f nanom aterials, but also in their functional applications [61]. One example is the
application o f nanofibers, which have been widely studied in the biomedical field,
including drug delivery. Their advantages are obvious, such as 1) drug loading is easy to
implement via electrospinning process; 2 ) the high applied voltage used in the
electrospinning process has negligible influence on drug activity; 3) they have high
specific surface area and short diffusion passage length which give the nanofiber drug
delivery system higher overall release rate than bulk materials; 4) the release profile can
be finely controlled by m odulation o f nanofiber morphology, porosity and composition
[61 ]. Therefore, electrospun nanofibers containing a HNTs based drug delivery system
was used to form a scaffold, which could be potentially developed into sutures and
widely used in surgeries. In this way, a local and sustained release o f antibiotics is
expected to prevent potential SSI after surgery.

6.2
6.2.1

M aterials and M ethods

M aterials
Halloysite nanoclay (H 4 Al 2

0 9

Si2 -2 H 2 0 , MW 294.19), Nitrofurantoin (C 8 H 5 N 4 O 5 ,

MW 238.16 g/mol), Sodium hydroxide solution (1 N), Hydrochloric acid solution (1 N),
Polyvinylpyrrolidone ((C 6 H 9 NO)x, M olecular W eig h t-1,3000,000), Poly(acrylic acid)
solution ( M olecular W eight-250,000, 35 wt.% in H 2 0 ), N ylon - 6 ((C 6 H nN O )n, mp 220
°C), LB Broth, and E. coli were obtained from Sigma Aldrich, St. Louis, MO.
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6.2.2

Light Sensitivity Test and Standard Calibration Curve
According to the product instruction, nitrofurantoin is sensitive to light, and the

impact o f light exposure on NFT needs to be examined first. Saturated NFT solution was
prepared, and its initial UV-Vis absorbance value was measured. Then, the solution was
kept under routine laboratory conditions without light protection. Samples o f the NFT
solution were collected and measured by UV-Vis every 24 hours. The results were
analyzed with IBM SPSS 22.0 to find any significant change during the light exposure.
To establish a standard calibration curve for the relationship between NFT
concentration and absorbance value, several N FT solutions with different known
concentrations were used (Table 6-1). Then, the standard calibration curve for NFT was
made through Excel (2007 Version).
6.2.3

Com posite Fabrication
In Chapter 4, three common fabrication methods were com pared, and the LbL

coating was proven to be best in performance o f both loading and releasing. Therefore,
the LbL coating was used to prepare HNTs for N FT loading. Polyvinylpyrrolidone (PVP)
and Poly(acrylic acid) (PAA) were used for the initial 18 layers o f LbL coating on the
outside surface o f HNTs. Then the FINT/polymer com posites were air dried and crushed
into fine powders. Next, 500 mg o f H NT/polym er composite was immersed into 5 ml
acetone, which contains NFT at the concentration o f 4 mg/ml. A stir bar was used to keep
stirring the suspension, which could help increase the contact between NFT and
HNT/polym er com posite. After 24 hours, the suspension was centrifuged, and the
supernatant was removed. The sedim ent was air dried and crushed into fine powders for
later use.
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6.2.4

M orphological Analysis: SEM
Pure HNTs and coated HNT/NFT com posites were examined using a scanning

electron microscope (Hitachi S-4800) to show the morphological change on the surface.
6.2.5

Drug Release Test
Twenty five milligram H NT/(PVP/PAA) 9 /NFT or reformed nylon composite

containing 25 mg H N T/(PVP/PA A ) 9 /NFT were immersed into 5 ml DI water. The
suspension was kept shaking for

10

minutes, and then centrifuged to collect the

supernatant for UV-Vis absorbance measurement. Residual supernatant was removed,
and fresh DI w ater was replenished. The process was repeated until slight am ounts o f
NFT were detected. N FT was assessed by spectroscopic m easurement at 370 nm.
6.2.6

Test Bacterium
For in vitro studies E. coli was used. The test strain was susceptible to N FT (MIC

32 ug/ml). E. coli was cultured within LB broth at 37 °C before testing.
6.2.7

A nti-Proliferation Tests
E. coli cells were resuspended in regular LB broth and adjusted to 1 * 108 cfu/ml

by

O D 6oo

measurement. Then bacterial suspensions

(3

ml) with regular broth and test

sam ples (G rouping seen in Table 6-1) were prepared in sealed plastic capillaries. Samples
were incubated for

6

hours at 37 °C, and OD 6 0 0 spectroscopic m easurem ent was used to

determ ine the changes o f cellular density in each sample.

77

Table 6-1: G ro u p in g o f s a m p le s fo r a n ti-p ro life ra tio n test.
Groups

Abbreviation

Standing for

Control

C

Blank Control

Sample 1

H

Pure HNTs

Sample 2

HP

HNT/(PVP/PAA),

Sample 3

HPN

HNT/(PVP/PAA)9/NFT

Sample 4

N

Nylon- 6

Sample 5

HPn

HNT/(PVP/PAA)»/Nylon- 6

HPNn

HNT/(PVP/PAAVNFT/Nylon- 6

Sample

6

6.3
6.3.1

Results

Standard Calibration Curve for NFT
As the nanodrop 2000c only has reliable accuracy when the absorbance value lies

between

0

and 1 , samples with high concentration were diluted before absorbance

measurement. Table 6-2 and Figure 6-1 show the results o f the standard calibration
curve for NFT. A clear linear relation between N FT concentration and absorbance value
was built within the spectroscopic range between 0 and 1, which is reliable (R 2 =0.999)
and was used for other tests.

Table 6-2: Standard calibration curve for N FT (wavelength: 370 nm).
Concentration

.5

1 .0

1.5

2 .0

2.5

3.0

3.5

4.0

4.5

5.0

.037

.076

.113

.154

.193

.229

.272

.308

.345

.384

(ug/ml)
Absorbance
Value
Standard

y = ,077x - .001 (R 2 = .999, y-absor aance value, x-NFT concentration

Curve

(ug/rrd))
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Standard Calibration Curve o f Nitrofurantoin
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0.4
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Figure 6-1: Standard Calibration Curve for NFT. A reliable (R 2 =.999) linear relation
between N FT concentration (ug/ml) and absorbance (370 nm) value showed up within
the spectroscopic range o f 0 to 1 .

6.3.2

Light Sensitivity Test for NFT
The light sensitivity test lasted three days (Table 6-3), and a declining trend o f

absorbance value could be clearly seen (Figure 6-2), which means NFT would degrade
slowly on light exposure. S analysis was applied, and the result shows that the sample
had been statistically different from its original status since the second day. On the other
hand, it also shows that NFT could not degrade com pletely in 24 hours. The majority o f
NFT m olecules stayed in solution (Table 6-3). For practical purposes, the degradation
could be ignored if all the required processes could be finished in one day.
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Table 6-3: L ig h t sen sitiv ity te st fo r N F T (w a v elen g th : 370 nm ).
Day-0

Day-1

Day-2

Day-3

Sample 1

.613

.587

.583

.565

Sample 2

.612

.600

.588

.569

Sample 3

.617

.593

.587

.573

Mean

.614

.593

.586

.569

SD

.003

.007

.003

.004

P

N/A

.0 0 2

.0 0 0

.0 0 0

(1) One-way ANOVA (IBM SPSS 22.0) was used to analyze the statistic difference
among these data.
(2) SD stands for standard deviation.
(3) All the samples o f NFT solution were 10 times diluted.

Light Sensitivity Test for NFT
0.63
0.62
„ 0.61

1

0.6

„ 0.59
| 0.58

|

0 5 7

1 0.56
< 0.55
0.54
0.53
Day 0

Day 1

Day 2

Day 3

Time Point

Figure 6-2: Result o f light sensitivity test for NFT. A clear declined trend o f the
absorbance value is seen, which means NFT degraded slowly because o f light
exposure.

80

6.3.3

Drug Coating
Electron scanning is a direct way to show the morphological change on the

outside surface o f HNTs after the fabrication process. Pure HNTs (Figure 6-3 A and B)
showed smooth outside surface, though some tubes had already shown a bright layer
because o f absorption o f water from air which could be seen as kind o f contamination.
NFT coated HNTs (Figure 6-3 C and D) also showed a bright layer on the outside as the
arrow pointed. The halloysite particle inflated and the tubular structure disappeared.
Some tubes clumped together, while the m ajority stayed uncoated, which suggested huge
loading potential for further fabrication.

Figure 6-3: Electron scanning images o f HNTs and coated HNTs. (A) and (B) are pure
HNTs, while (C) and (D) are coated HNTs (HN T/( P V P/P A A )<>/NF T ).
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An indirect method was used to measure the loading amount o f NFT on
H NT/(PVP/PA A ) 9 com posites. 25 mg HNT/(PVP/PAA)</NFT was immersed into 500 ml
DI w ater for a com plete release o f NFT. Sample solution was collected, centrifuged, and
measured by UV-Vis spectroscopy. According to the above relationship between the NFT
concentration and absorbance value, the result o f .030 could be translated into .403
ug/ml, and the released NFT was 201.3 ug. In this way, 1 mg HNT/(PVP/PAA) 9 /NFT
was calculated to carry about 8.1 ug NFT.
6.3.4

Drug Release from HNTs
F1 NT/(PV P/PA A ) 9 and HNT/(PVP/PAA) 9 /NFT com posites were directly mixed

within nylon - 6 solution (formic acid) individually (Figure 6-4 A). After complete
evaporation o f formic acid, sample disks (pure nylon- 6 , H N T /(PV P/PA A V nylon- 6 , and
H N T/(PV P/PA A V N FT/nylon- 6 ) were formed (Figure 6-4 B). 25 mg
H NT/(PVP/PAA)9/N FT and sample disks which contain 25 mg H N T/(PV P/PA A V N FT
were immersed into 5 ml Dl water for NFT release test.

Figure 6-4: Incorporation o f nylon - 6 with H N T/(PV P/PA A ) 9 and
H NT/(PVP/PAA) 9 /N FT composites. Groups: nylon - 6 (Row A), H NT/(PV P/PA A ) 9
(Row B), and FTNT/(PVP/PAA)9 /NFT (Row C). After the complete evaporation o f
formic acid, sample disks formed.
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In Figure 6-5, the release cycles for both HNT/(PVP/PAA) 9 /NFT and
HNT/(PVP/PA A ) 9 /N FT/nylon - 6 ran 14 times as no more released NFT could be detected
by the nanodrop. There was a burst release in both o f groups, and the one o f
H NT/(PVP/PAA) 9 /N FT was much higher than the other (Figure 6-5 A). Then the release
decreased sharply at the second and third cycle, after which it went mildly until the end.

Release Test o f Nitrofurantoin
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Figure 6-5: Release test o f NFT. The total release cycle ran 14 times. (A) shows the
individual release for each cycle, and (B) shows the total percentage o f release by each
cycle.
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In Figure 6-5 (B), H NT/(PVP/PAA) 9 /N FT com posites had a higher release
percentage than its nylon - 6 counterpart, which m eans by the end o f the test, there was
still some NFT not released from FfNT/(PVP/PAA) 9 /N FT/N ylon- 6 , which may help
increase the release period.
6.3.5

Bacterial Anti-Proliferation Test
In Figure 6-6, (A) and (C) show the initial images o f the E. coli culture in each

group. In the groups o f HNT, H N T/(PVP/PA A ) 9 and H N T/(PVP/PA A ) 9 /NFT, the broths
were a little turbid because o f the suspension o f sam ple powders. While in the other
groups, the broths were relatively clear. Sample pow ders and disks were clearly seen in
the broths.

Figure 6-6: A nti-proliferation test o f N FT with E. coli. Group description: C^Control,
H=HNTs, HP=FTNT/(PVP/PAA)9, HPN= H N T/(PVP/PA A ) 9 /NFT, N= N ylon- 6 , HPn=
HNT/(PVP/PAA) 9 /N ylon- 6 , HPNn= HNT/(PVP/PA A ) 9 /N FT/N ylon- 6 . (A) and (C)
show the initial images o f bacterial culture, while (B) and (D) show their images after 6
hours.

Figure

6 -6

(B) and (D) show the images o f E. coli culture o f six hours. Except for

the groups o f H NT/(PVP/PAA) 9 /N FT and HNT/(PVP/PA A ) 9 /N FT/N ylon- 6 , all the other
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groups present oyster white turbidity, which made them look the same. In group o f
HNT/(PVP/PAA) 9 /NFT, the sample powders were seen in the bottom as sediment. It is
the same with the group o f HNT/(PVP/PAA)i)/NFT/Nylon - 6 where sample disks stayed
intact within the broth.
Table 6-4 and Figure 6-7 show the result o f spectroscopic measurement o f the
broth in each group at 600 nm. After

6

hours, E. coli proliferated very well in the control

group with a much higher spectroscopic value. In the groups containing tested powders,
the values in both groups o f HNT and H N T/(PVP/PA A ) 9 were higher than that in fhs
control group, while it became very low in the group o f H NT/(PVP/PAA) 9 /NFT. In the
other three groups with tested disks, the values in groups o f NyIon - 6 and
HNT/(PVP/PAA) 9 /N ylon - 6 were a little lower than the control, and the one in the
HNT/(PVP/PAA) 9 /NFT/NyIon - 6 was much lower, which was also very close to that in
the initial group.

Table 6-4: Result o f anti-proliferation test o f nitrofurantoin with E. coli.
E. coli

HNT

(Control)

HNT

HNT

Polymer

Nylon-6

HNT

HNT

Polymer

Polymer

Polymer

NFT

Nylon-6

NFT
Nylon-6

Sample 1

.918

.686

1.236

.131

.906

.853

.045

Sample 2

.914

.681

1.215

.129

.891

.858

.044

Sample 3

.935

.661

1.222

.123

.912

.864

.048

Mean

.922

.676

1.224

.128

.903

.858

.046

SD

.0 1 1

.013

.004

.0 1 1

.006

.002

.0 1 1

(1). OD 6 0 0 value is directly re ated to the cellular density o f E. coli in broth,
(2). The spectroscopic measui■ement o f the initial E. coli was .040.
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Figure 6-7: Anti-proliferation test o f NFT with E. coli.

Statistical analysis was applied with one-way ANOVA (IBM SPSS Statistics 22).
The initial group was not included in the results as it is not normally distributed. A
Shapiro-W ilk’s test (P>.05) showed that the spectroscopic values were approxim ately
normally distributed for all the groups. A Levene’s test verified the equality o f variances
in the samples (homogeneity o f variance) (P>.05). In T able 6-5: Statistical analysis o f
anti-proliferation test., only the groups o f control and N ylon - 6 were statistically same,
while all the others were different. Additionally, the spectroscopic value in the group o f
HNT/(PVP/PAA) 9 /N FT/N ylon - 6 was very close to that o f the initial, which suggested the
bacterial proliferation was com pletely inhibited.
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Table 6 -5 : S ta tistica l a n a ly sis o f a n ti-p ro life ra tio n test.

C

H

HP

HPN

N

HPn

HPNn

c
n

N/A

.000
N/A

.000
.000

.199

.000

.000
.000

.000
.000

.000
.000

HP

.000
.000
.000
.000

N/A

.000

.000
.000
.000

N/A

.000
.000

N/A

.000
.000
.001

HPn

.000
.000
.199
.000

.001

N/A

.000
.000
.000
.000

HPNn

.000

.000

.000

.000

.000

.000

N/A

HPN
N

.000
.000
.000

Sample size n=3

6.4
6.4.1

Discussion

Strategy Novelty
Surgical site infection (SSI) is a com mon postoperative com plication in surgery,

which may cause serious consequent to patients in both finance and health. A routine and
efficient way to prevent SSI is the application o f antibiotics during the perioperative
period, which mainly includes enteral adm inistration and parenteral route. In the former
class, there are three methods o f adm inistration including oral, sublingual, and rectal.
Drugs given by enteral adm inistration (except rectal way) are subjected to significant first
pass metabolism through the liver, and the am ount o f drug entering the systemic
circulation would vary significantly for different individuals and drugs [62]. In the
parenteral course, drugs can be given through veins, arteries, muscles, spinal canal, and
skins. After entering the systemic circulation, drugs will be distributed evenly in the
blood stream around the whole body. Only a small fraction o f drug m olecules are
delivered to sites where their actions are expected, and the rest can expose normal tissues
to risk o f side reactions.
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The application o f HNTs based drug delivery system can change this situation.
Nitrofurantoin was used in this project as an example. On the one hand, NFT could be
directly released from tem porary body implants (like sutures, staples, glues and tapes) to
sites o f action, which can greatly improve drug efficiency. On the other hand,
unnecessary exposure o f N FT to regular tissues can be avoided, and patients will not
suffer from any side reaction.
A nother benefit o f this strategy comes from the extension o f drug application. In
this project, NFT has good activity against many bacteria including E. coli, S. aureus, and
E. fa e c a l is, which are also included in the list o f common pathogens for surgical site
infection. Besides, N FT has a preference o f bacterial cells over mammalian cells, and
acquired resistance in sensitive bacteria is relatively rare. However, its clinical
application is limited to urinary tract infection because o f some limitations like low
bioavailability, poor tissue penetration, and fast metabolism by liver [60], By applying
the strategy o f directly delivering N FT to sites o f action, all the above problems
disappeared and N FT became a good alternative for the prevention o f SSI.
6.4.2

Advantage o f Laver-bv-Laver Coating
In Chapter 4, three com mon m ethods have been compared, and the layer-by-layer

technique showed better performance in both drug loading and releasing than the other
two. Therefore, the LbL technique was used for the fabrication o f HNT based drug
delivery vehicle in this experiment. Theoretically, the built LbL structure on the outside
surface o f HNTs could be used to trap N FT molecules, and the more layers there were,
the more m olecules would be held inside the LbL base. M eanwhile, the release period
would be extended correspondingly with the increased layers.
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The LbL technique is an easy and cheap process with no specially required
equipment. The drug layer could be placed anywhere inside the LbL structure according
to the application goal. In this preliminary experim ent, as NFT was the only tested drug,
it was placed on the most outside layer to 1) achieve a burst release at the start o f the
release process and reach the required drug concentration for N FT’s antibiotic action
(M IC90 for E. coli is 32 ug/ml [63]), 2) avoid unnecessary loss o f N FT in process o f
adding extra layers. W hat’s more, one drug could be theoretically incorporated multiple
times during the fabrication process, and more than one drug could be included in the
LbL design.
6.4.3

Release Properties
An ideal drug delivery system should not release drugs too fast or too slow.

Released drugs need to stay above a required concentration to take action, and the status
should continue until achievem ent o f the expected result. The HNTs based drug delivery
system showed a potential for such properties in release tests. The main driving force for
the N FT release was the concentration gradient between D1 water and HNT/polym er
nanoparticles. Once entering aqueous solution, N FT m olecules started to move, and the
net direction was from HNT to DI water, which was opposite to that in the fabrication
process. This trend lasted until a balance was reached, w here the net m oving o f NFT
molecules stopped. A fter the replenishm ent with fresh DI water, a new concentration
gradient, which was sm aller than the prior one, formed between HNT and DI w ater
leading to another cycle o f N FT release. In this way, the release period was partially
determ ined by the consum ing rate o f drugs by surrounding environment. The
concentration gradient also determ ined the release rate, which could well explain the fast
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release at the initial stage and slow release at the end. Besides, the LbL structure could
also affect the release process, as N FT m olecules trapped between different layers might
present different release spans. Finally, by com paring the release results o f
HNT/(PVP/PAA)9/NFT and HNT/(PVP/PA A )9/NFT/Nylon-6, the filling o f coated HNT
into nylon-6 could help slow down rather than inhibit the release process. This property
enabled the HNT delivery system have more potential in nylon-6 based applications.
6.4.4

Anti-Proliferation Test with E. coli
In F ig u re 6-7, the increased O D 6 0 0 value in the control group, com pared with the

initial, showed the bacterial growth during the past 6 hours. To avoid the sedim ent o f
bacterial cells, no centrifuge operation was done with the samples. Although left standing
for a while, there were still some HNTs or coated HNTs suspending in the broth which
may affect the spectroscopic m easurem ent o f the bacterial density.
In the groups o f HNTs and coated HNTs, their O D 6 0 0 values represented the
absorbance o f both E. coli and HNTs or coated HNTs. Fortunately, in the group o f
HNT/(PVP/PAA)9/NFT whose O D 6 0 0 values was .128 ± .004, it suggested that the
increased OD 6 0 0 values caused by HNTs or coated HNTs should be sm aller than .128.
Given the values in the group o f HNTs (1.676 ± .013) and H N T/(PVP/PA A )9( 1.224 ±
.011), the bacterial growth should not have been inhibit. Instead, the bacterial growth was
stimulated to increase to some degree. At least, both HNT and H N T/(PVP/PA A )9were
not harmful to E. coli. Compared with the control group o f E. coli, the decreased value in
group o f HNT/(PVP/PAA)9/N FT was caused only by the release o f NFT. There was also
a significant decrease in the group o f H N T/(PVP/PA A )9 when com pared with group o f
HNT. The reason could be the pH change caused by polym er layers because they were

90

fabricated in a strong acid environm ent (pH=3), which com prom ised the stim ulant effect
o f HNT on E. coli.
In the rest groups o f nylon- 6 , HNT/(PVP/PAA) 9 /N ylon- 6 , and
HNT/(PVP/PAA) 9 /N FT/N ylon- 6 , the values only represented the growth o f bacteria as
the coated HNT powders were filled in the nylon - 6 matrices rather than suspended in the
broth. The values in the group o f nylon - 6 were statistically the same as that o f the control
group, which proved that the nylon - 6 disks in the broth did not affect the bacterial growth
in the past six hours. Although formic acid has been reported to be very efficient in
reducing the population o f E. coli [64] and it was used to prepare the solution o f nylon- 6 ,
the result in Group nylon - 6 could well confirm the complete evaporation o f formic acid
during fabrication process.
On this basis, the slight decrease in the group o f H NT/(PVP/PAA) 9 /N ylon - 6 could
be due to the pH change caused by the coated polymers, and the huge difference between
the group o f HNT/(PVP/PAA) 9 /N FT/N ylon - 6 and the control was only caused by the
released NFT. To be more specific, the spectroscopic value in the group o f
HNT/(PVP/PAA) 9 /N FT/N ylon - 6 (.046 ± .002) was ju st slightly higher than that o f initial
E. coli (.040) as N FT could well inhibit bacterial proliferation but not kill them.
6.4.5

Challenge
During the fabrication o f layer-by-layer structure, the coated HNT particles could

easily clum p together, which may stop further coating o f more layers. As seen in F igure
6-3 (C) and (D), even after the process there were still a lot o f HNTs staying uncoated.
Therefore, more study is required to increase the ratio o f coated HNT versus uncoated
ones, which reserves a huge room for the drug loading improvement.
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6.5

Conclusions

Hailoysite nanotubes did not provoke a cytotoxic effect on E. coli cells nor inhibit
their proliferation ability. Nitrofurantoin was incorporated into a PE coating and observed
released from the coating. Released N FT resulted in a reduction in bacterial proliferation.
After the NFT-coated HNTs were mixed with N ylon- 6 , the releasing ability o f N FT was
preserved, and the released NFT also inhibited bacterial proliferation. As a
nanocom posite drug delivery system, N FT coated HNTs show a potential for the delivery
o f antibiotic drugs. W hile NFT was the drug used in this study, there is also a potential
for the system to incorporate other drugs. The system also has the potential to insert drugs
at different coating depths that may perm it multiple, combinatorial or even sequential
release depending on coating architecture and composition.

CHAPTER 7
C O N C L U SIO N S AN D FUTURE W O R K

7.1

Conclusions

In this dissertation, halloysite nanotubes were studied as nano-carriers to load and
release drugs (m ethotrexate and nitrofurantoin) for potential clinical applications. Three
com mon fabrication methods were compared including physical adsorption, vacuum
loading, and layer-by-layer coating. The drug loaded halloysite com posites were filled
within nylon- 6 , and continuously provided a sustained release o f loaded drugs. In vitro
osteosarcom a cell test and in vitro E. coli test confirmed the intact biological functions o f
released drugs. In this way, the halloysite based drug delivery system showed a potential
medical application and provided another option for drug delivery.
Physical adsorption and vacuum loading are com m on methods used for HNT
fabrication, while layer-by-layer coating was studied as a novel method to prepare the
HNT based drug delivery vehicle. M ethotrexate was used as the model drug to be
delivered, and the LbL coating method had better performance than the other two in both
loading and releasing. Therefore, LbL coating was used for drug loading in subsequent
experiments.
Osteosarcom a is the most com mon m alignant bone cancer in children and
adolescents, and local relapse was a main cause o f death after surgical remove o f the
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prim ary tum or mass. One important strategy is to prevent postoperative recurrence,
which is the main target o f the newly formed HNT-based drug delivery system. LbL
technique was applied, and MTX was loaded within the LbL layers. Then the MTX
coated HNTs com posites were added within nylon - 6 as fillers. Pure HNTs and
HNT/PE/nylon com posites did not provoke a cytotoxic effect on osteosarcom a cell nor
inhibit their proliferation ability, but the released MTX caused significant decrease in cell
proliferation. Even after the MTX coated HNTs were mixed within nylon- 6 , the releasing
ability o f MTX was preserved, and its anti-proliferation function was kept intact. As a
nanocom posite drug delivery system, MTX coated HNTs showed a potential to deliver
antitum or drugs directly to sites o f action to prevent future relapse. The system also holds
a potential to incorporate other drugs at different coating depths that may permit multiple,
com binatorial, or even sequential release depending on coating architecture and
composition.
Surgical site infection is a com mon and feared complication. It can cause
considerable consequences for patients and high medical costs for society. One potential
strategy to improve the current treatment result is to enhance the efficacy o f routine
antibiotics. The nitrofurantoin coated HNTs drug delivery system provides such an
option. N FT coated HNTs presented a burst initial release followed by sustained mild
drug liberations in DI water. A fter being filled in nylon- 6 , the releasing ability was
preserved and the release became milder and longer. In the in vitro bacterial anti
proliferation test, the N FT coated HNT showed efficient inhibition on the bacterial
growth, suggesting a potential in the prevention o f SSL
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7.2
7.2.1

Future W ork

Improving Loading Efficiency
U nder routine laboratory condition, one hard challenge with the HNT fabrication

is to improve the loading efficiency. In both Figure 4-2 and Figure 6-4, it clearly showed
that a big ratio o f HNTs stayed uncoated after fabrication. Regular vortex m achine and
shaker cannot com pletely separate the nanoparticles after centrifuge, leaving them in
clumps. Therefore, there is still a huge space for further coating, which holds a potential
for increasing the drug loading ability. M aybe a high frequency sonicater is a possible
solution? However, its impact on the layer-by-layer structure needs to be considered as
well.
7.2.2

Tunable Laver-bv-layer Fabrication
The layer-by-layer fabrication method is an easily controllable process, as each

layer’s coating is an independent process. Factors like polyelectrolytes, concentration,
pH, and solvent can greatly impact the properties o f the built layer-by-layer structure. It is
potential to endow the LbL structure different properties by tuning these factors.
7.2.3

M ultiple and Sequential Drug Delivery
Theoretically, there is little limitation in the layer-by-layer coating. The target

drug could be coated at any depth w ithin the LbL structure, and multiple drugs could be
coated at different depths. Therefore, there is a potential for multiple and sequential drug
delivery with the HNT based system. Further studies o f the release profile for the
sequential drug release will continue in Dr. M ills’ lab.
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7.2.4

In Vivo Animal Test
Preliminary in vitro tests with both osteosarcom a cells and E. coli have

individually confirmed the feasibility o f applying HNTs based drug delivery system in
the treatment o f cancer and surgical site infection. To further verify the hypothesis about
the practical potential o f HNT based drug delivery system, animal test is required.
Potentially target medical supplies like bone cem ent, sutures, and tissue scaffold could be
made through technologies including electrospinning, electrospray, and 3-D printing.
Chem otherapeutics, antibiotics, and hormones could be loaded with HNT based system
and then filled within aforem entioned medical products. Animal models are planned to
test the feasibility o f drug delivery through HNT based systems.
This dissertation presents three simple methods for drug delivery with halloysite
nanotubes. Two preliminary in vitro tests were showed to foresee potentially future
application in medical field. I hope these studies could provide another option for the
research in drug delivery.
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